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A B S T R A C T
Background
This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.
Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to
nasal blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps.
Topical (intranasal) corticosteroids are used with the aim of reducing inflammation in the sinonasal mucosa in order to improve patient
symptoms.
Objectives
To assess the effects of different types of intranasal steroids in people with chronic rhinosinusitis.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015,
Issue 7); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of
the search was 11 August 2015.
Selection criteria
Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing first-generation intranasal corticos-
teroids (e.g. beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) with second-generation intranasal cor-
ticosteroids (e.g. ciclesonide, fluticasone furoate, fluticasone propionate, mometasone furoate, betamethasone sodium phosphate), or
sprays versus drops, or low-dose versus high-dose intranasal corticosteroids.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related
quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis (nosebleed). Secondary outcomes
included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse event of local
irritation. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included nine RCTs (911 participants), including four different comparisons. None of the studies evaluated our first primary
outcome measure, disease-specific HRQL.
Fluticasone propionate versus beclomethasone dipropionate
We identified two small studies (56 participants with polyps) that evaluated disease severity and looked at the primary adverse effect:
epistaxis , but no other outcomes. We cannot report any numerical data but the study authors reported no difference between the two
steroids. The evidence was of very low quality.
Fluticasone propionate versus mometasone furoate
We identified only one study (100 participants with polyps) that evaluated disease severity (nasal symptoms scores), which reported
no difference (no numerical data available). The evidence was of very low quality.
High-dose versus low-dose steroids
We included five studies (663 participants with nasal polyps), three using mometasone furoate (400 µg versus 200 µg in adults and
older children, 200 µg versus 100 µg in younger children) and two using fluticasone propionate drops (800 µg versus 400 µg). We
found low quality evidence relating to disease severity and nasal polyps size, with results from the high-dose and low-dose groups being
similar. Although all studies reported more improvement in polyp score in the high-dose group, the significance of this is unclear due
to the small size of the improvements.
The primary adverse effect, epistaxis , was more common when higher doses were used (risk ratio (RR) 2.06, 95% confidence interval
(CI) 1.20 to 3.54, 637 participants, moderate quality evidence). Most of the studies that contributed data to this outcome used a broad
definition of epistaxis, which ranged from frank bleeding to bloody nasal discharge to flecks of blood in the mucus.
Aqueous nasal spray versus aerosol spray
We identified only one poorly reported study (unclear number of participants for comparison of interest, 91 between three treatment
arms), in which there were significant baseline differences between the participants in the two groups. We were unable to draw
meaningful conclusions from the data.
Authors’ conclusions
We found insufficient evidence to suggest that one type of intranasal steroid is more effective than another in patients with chronic
rhinosinusitis, nor that the effectiveness of a spray differs from an aerosol. We identified no studies that compared drops with spray.
It is unclear if higher doses result in better symptom improvements (low quality evidence), but there was moderate quality evidence of an
increased risk of epistaxis as an adverse effect of treatment when higher doses were used. This included all levels of severity of epistaxis
and it is likely that the proportion of events that required patients to discontinue usage is low due to the low numbers of withdrawals
attributed to it. If epistaxis is limited to streaks of blood in the mucus it may be tolerated by the patient and it may be safe to continue
treatment. However, it may be a factor that affects compliance.
There is insufficient evidence to suggest that the different types of corticosteroid molecule or spray versus aerosol have different effects.
Lower doses have similar effectiveness but fewer side effects.
Clearly more research in this area is needed, with specific attention given to trial design, disease-specific health-related quality of life
outcomes and evaluation of longer-term outcomes and adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Different types of intranasal steroids for chronic rhinosinusitis
Review question
We reviewed the evidence for the benefits and harms of different types of intranasal (in the nose) steroids given to people with chronic
rhinosinusitis.
Background
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Chronic rhinosinusitis is a common condition that is defined as inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients with chronic rhinosinusitis experience at least two or more of the following symptoms
for at least 12 weeks: blocked nose, discharge from their nose or runny nose, pain or pressure in their face and/or a reduced sense of
smell (hyposmia). Some people will also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the nasal
passage and sinuses. Topical (intranasal) corticosteroids are used with the aim of reducing inflammation in order to improve patient
symptoms.
Study characteristics
We included nine randomised controlled trials (RCTs) with a total of 910 participants in this review. The studies varied in size: some
were small, with as few as 20 patients, while others included over 200 participants. Most studies recruited adult patients, but one
study only included children. In the majority of the adult studies, most participants were male (72% to 79%). In all of the studies the
participants had chronic rhinosinusitis with nasal polyps. The studies either compared different types of steroids (three studies), high-
dose versus low-dose steroids (five studies), twice daily versus once daily steroids, or different delivery methods (aqueous nasal spray
versus aerosol - one study). All of the studies had a placebo group.
Key results and quality of the evidence
Different steroids: fluticasone propionate versus beclomethasone dipropionate
Two small studies (56 participants, unclear risk of bias) evaluated disease severity and looked at the primary adverse effect, epistaxis
(nosebleed), but no other outcomes. No difference was found between the two steroids but we assessed the evidence to be of very low
quality.
Different steroids: fluticasone propionate versus mometasone furoate
One study (100 participants, unclear risk of bias) found no difference in disease severity (nasal symptoms scores). We assessed this
evidence to be of very low quality.
High-dose versus low-dose steroids
We found five studies (663 participants, low or unclear risk of bias) that compared high-dose and low-dose steroids, three using
mometasone furoate (400 µg versus 200 µg in adults and older children, 200 µg versus 100 µg in younger children), and two using
fluticasone propionate drops (800 µg versus 400 µg). Effectiveness (disease severity and nasal polyps size) was similar between the high-
dose and low-dose groups (low quality evidence). Although all studies reported more improvement in polyp score in the high-dose
group, the significance of this is unclear because the improvements seen were small.
The primary adverse effect, epistaxis, was more common when higher doses were used (moderate quality evidence).
Different delivery methods: aqueous nasal spray versus aerosol spray
We identified only one poorly reported study with a high risk of bias. It was unclear howmany participants there were: 91 were recruited
into three arms. There had also been significant differences between the participants in the two groups when they started the study. We
were unable to draw any meaningful conclusions from this study.
Conclusions
We found no evidence that one type of intranasal steroid is more effective than another in patients with chronic rhinosinusitis, nor that
higher doses are better than lower, nor that the effectiveness of a spray differs from an aerosol. We found no studies that compared nasal
drops with spray. We did find moderate quality evidence of an increased risk of epistaxis (nosebleed) as an adverse effect of treatment
when higher doses were used.
More research in this area is clearly needed. In the future studies should be well designed: they should measure chronic rhinosinusitis-
specific health-related quality of life and adverse effects as outcomes, and look at what happens to patients taking intranasal steroids in
the longer term.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Different types of intranasal corticosteroid molecules for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is (all studies recruited pat ients with bilateral polyps)
Setting: Europe/ North America about 20 years ago, in secondary care sett ings
Intervention: f lut icasone propionate
Comparison: beclomethasone dipropionate or mometasone furoate
Outcomes
of participants
(studies)
Relative effect (95%) Anticipated absolute effects∗ (95% CI) Quality What happens
Low-dose intranasal
corticosteroids
High-dose intranasal
corticosteroids
Difference
Disease-specif ic
health-related quality of
lif e
Not measured Impact unknown
Disease severity - over-
all symptoms
• Study 1: 37
part icipants
• Study 2: 19
part icipants
• Study 3: 100
part icipants
- • Study 1 (f lut icasone propionate versus beclomethasone
dipropionate): seemed to report results select ively, showing
some benef its of f lut icasone propionate for some symptoms
• Study 2 (f lut icasone propionate versus beclomethasone
dipropionate): reported a ‘‘t rend’’ towards less severity with
f lut icasone propionate compared to beclomethasone
dipropionate
• Study 3 (f lut icasone propionate versus mometasone
furoate): reported no stat ist ically signif icant dif f erences
⊕©©©
VERY LOW 123
No dif ferences observed but evi-
dence was too low quality to draw
a conclusion
Adverse events: epis-
taxis
• Study 1: 37
part icipants
• Study 2: 19
part icipants
• Study 3: 100
part icipants
- • Study 1 (f lut icasone propionate versus beclomethasone
dipropionate): 13/ 19 in f lut icasone propionate group and 16/
18 in beclomethasone dipropionate group had some form of
adverse event, including epistaxis
• Study 2 (f lut icasone propionate versus beclomethasone
dipropionate): 7/ 10 in f lut icasone propionate group and 3/ 10
in beclomethasone dipropionate group had epistaxis
• Study 3 (f lut icasone propionate versus mometasone
furoate): both drugs were ‘‘well tolerated’’
⊕©©©
VERY LOW 123
Unclear whether the risk of epis-
taxis varies for dif f erent types of
steroid molecules
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Studies were either very small (n = 20 and n = 26) and had important drop-outs or were only reported as an abstract with
inadequate information available (n = 100). We considered all studies to be at unclear to high risk of select ive report ing
and attrit ion bias. The evidence was very low quality due to very serious imprecision and very serious risk of bias concerns.
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B A C K G R O U N D
Description of the condition
Chronic rhinosinusitis is defined as inflammation of the nose and
paranasal sinuses characterised by two or more symptoms, one of
whichmust be nasal blockage/obstruction/congestion or nasal dis-
charge (anterior/posterior nasal drip). The other possible symp-
toms include facial pain/pressure, reduction or loss of sense of
smell (in adults) or cough (in children). Symptomsmust have con-
tinued for at least 12 weeks. In addition people must have either
mucosal changes within the ostiomeatal complex and/or sinuses as
evidenced by a computerised tomography (CT) scan and/or endo-
scopic signs of at least one of the following: nasal polyps, mucop-
urulent discharge primarily from middle meatus or oedema/mu-
cosal obstruction primarily in the middle meatus (EPOS 2012).
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptoms, including
nasal obstruction, nasal discharge, facial pain, anosmia and sleep
disturbance, have a major impact on quality of life, reportedly
greater in several domains of the SF-36 than angina or chronic res-
piratory disease (Gliklich 1995). Acute exacerbations, inadequate
symptom control and respiratory disease exacerbation are com-
mon. Complications are rare, but may include visual impairment
and intracranial infection.
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them.
The most commonly used interventions for chronic rhinosinusitis
are used either topically (sprayed into the nose) or systemically (by
mouth) and include steroids, antibiotics and saline.
Description of the intervention
Anti-inflammatory therapy plays a significant role in the treatment
of chronic rhinosinusitis. This includes corticosteroids and low-
dosemacrolides. Topical corticosteroids are more widely used than
oral steroids because treatment can be given for longer without
significant adverse effects.
Intranasal corticosteroid therapy is often prescribed for patients
with chronic rhinosinusitis, but with considerable variability in
timing, frequency, dose, topical delivery method and the specific
agent used (Benninger 2003; Spector 1998). The topical delivery
method significantly affects the amount of steroid that comes into
contact with the paranasal sinus mucosa (Grobler 2008; Harvey
2009). The simplest nasal delivery methods are drops, sprays,
aerosols, nebulisers and atomisers. These contrast with meth-
ods involving direct sinus cannulation and nasal irrigation with
squeeze bottles and neti pots, which are likely to provide better
delivery to the sinuses, especially in the post-sinus surgery setting
(Grobler 2008; Harvey 2009; Thomas 2013).
Classes of topical corticosteroid include first-generation intranasal
steroids (beclomethasone dipropionate, triamcinolone acetonide,
flunisolide and budesonide) and newer preparations (fluticas-
one propionate, mometasone furoate, ciclesonide and fluticasone
furoate).
How the intervention might work
The use of topical (intranasal) corticosteroids has been widely ad-
vocated for the treatment of chronic rhinosinusitis given the be-
lief that inflammation is a major component of this condition
(Fokkens 2007; Hamilos 2000; McNally 1997). The mechanism
of action is a combination of anti-inflammatory effects (for ex-
ample, reducing pro-inflammatory, and increasing anti-inflamma-
tory, gene transcription and reducing airway inflammatory cell
infiltration) and suppression of the production of pro-inflamma-
tory mediators, cell chemotactic factors and adhesion molecules
(Mullol 2009). Different steroids, in different doses, delivered in
different ways (as sprays versus drops, for example) may differ in
their effectiveness. The adverse effects may also differ.
Why it is important to do this review
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Intranasal corticosteroids are the mainstay and currently recom-
mended treatment for chronic rhinosinusitis. This review incor-
porates an update of two previous Cochrane reviews (Kalish 2012;
Snidvongs 2011). This review is important because it addresses
the important clinical question of which type, dose or delivery
method of intranasal corticosteroids is most effective or safe for the
treatment of chronic rhinosinusitis. Unlike the companion review
that seeks to establish the effectiveness of intranasal corticosteroids
versus placebo (Chong 2016a), this review looks at studies that
provide head to head comparisons of these factors.
This review is one of a suite of Cochrane reviews looking at com-
monmanagement options for patients with chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Head 2016a; Head 2016b; Head
2016c), and we use the same outcome measures across the reviews.
We have not included studies designed to evaluate interventions
in the immediate peri-surgical period, which are focused on as-
sessing the impact of the intervention on the surgical procedure
or on modifying the post-surgical results (preventing relapse).
O B J E C T I V E S
To assess the relative effects of different types, delivery methods
and doses of intranasal corticosteroids.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only to
be included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of intranasal corticosteroids on
surgical outcome.
Types of participants
Patients with chronic rhinosinusitis, whether with or without
polyps.
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• allergic fungal sinusitis/eosinophilic fungal/mucinous
rhinosinusitis;
• aspirin-exacerbated respiratory disease;
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps;
• primary ciliary dyskinesia
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Types of interventions
All intranasal corticosteroids; this included nasal sprays and nasal
drops.
First-generation intranasal corticosteroids:
• Beclomethasone dipropionate
• Triamcinolone acetonide
• Flunisolide
• Budesonide
Second-generation intranasal corticosteroids:
• Ciclesonide
• Fluticasone furoate
• Fluticasone propionate
• Mometasone furoate
• Betamethasone sodium phospate
If other interventions were used, these should have been used in
both treatment arms. Allowed co-interventions included:
• nasal saline irrigation;
• antibiotics; and
• intermittent nasal decongestants.
The main possible comparison pair was:
• any first-generation corticosteroid versus any second-
generation corticosteroid.
Other possible comparison pairs were:
• intranasal corticosteroid delivered as spray versus intranasal
corticosteroid delivered as drops; and
• low-dose intranasal corticosteroid versus high-dose
intranasal corticosteroid.
This review is part of a larger series of six reviews for the treatment
of chronic rhinosinusitis.
• Intranasal steroids versus placebo or no intervention for
chronic rhinosinusitis (Chong 2016a).
• Different types of intranasal steroids for chronic
rhinosinusitis (this review). This review compares different
classes, doses and delivery methods of intranasal corticosteroids
for chronic rhinosinusitis.
• Short-course oral steroids alone for chronic rhinosinusitis
(Head 2016a). This review compares short-course oral steroids
alone with placebo or no intervention, or against other
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pharmacological interventions such as antibiotics or nasal saline
irrigation.
• Short-course oral steroids as an adjunct therapy for chronic
rhinosinusitis (Head 2016b). This review compares oral steroids
where they have been used as add-on therapy to other treatments
for chronic rhinosinusitis (such as intranasal corticosteroids,
antibiotics or saline solution).
• Saline irrigation for chronic rhinosinusitis (Chong 2016b).
This review compares nasal saline irrigation for chronic
rhinosinusitis with both placebo/no intervention and with
intranasal corticosteroids or antibiotics.
• Systemic and topical antibiotics for chronic rhinosinusitis
(Head 2016c). This review compares both topical and systemic
antibiotics with placebo/no treatment, two different antibiotics
with each other and antibiotics with intranasal corticosteroids.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, we reported patient-reported individual symptom
scores for the following symptoms: nasal obstruction/blockage/
congestion, nasal discharge (rhinorrhoea), facial pressure/pain,
loss of sense of smell (adults) and cough (children).
• Significant adverse effect: epistaxis.
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other adverse effects: local irritation (including oral thrush,
sore throat and other local nasal irritation such as dryness,
itchiness etc.).
• Other adverse effects:
◦ in children - stunted growth (minimum time point:
six months of treatment and follow-up);
◦ in adults - osteoporosis.
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
Outcomes were measured at three to six months, six to 12 months
and more than 12 months. For adverse events, we analysed data
from the longest time periods.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 11 August 2015.
Electronic searches
The Information Specialist searched:
• the Cochrane Register of Studies ENT Trials Register
(searched 11 August 2015);
• the Cochrane Central Register of Controlled Trials
(CENTRAL 2015, Issue 7);
• Ovid MEDLINE (1946 to July week 5 2015);
◦ Ovid MEDLINE (In-Process & Other Non-Indexed
Citations) (searched 11 August 2015);
◦ PubMed (as a top up to searches in Ovid MEDLINE)
(searched 11 August 2015);
• Ovid EMBASE (1974 to 2015 week 32);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies) (searched 11 August 2015);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (searched 11 August 2015);
• Google Scholar (searched 11 August 2015).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochraneHandbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors where necessary. In addi-
tion, the Information Specialist searched PubMed, The Cochrane
Library and Google to retrieve existing systematic reviews relevant
to this systematic review, so that we could scan their reference lists
for additional trials.
Data collection and analysis
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Selection of studies
At least two review authors independently screened all titles and
abstracts of the studies obtained from the database searches to
identify potentially relevant studies. At least two review authors
evaluated the full text of each potentially relevant study to deter-
mine if it met the inclusion and exclusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and/methodological
input where necessary.
Data extraction and management
Two review authors independently extracted data from each study
using a standardised data collection form (see Appendix 2).When-
ever a study had more than one publication, we retrieved all pub-
lications to ensure complete extraction of data. Where there were
discrepancies in the data extracted by different review authors, we
checked these against the original reports and resolved differences
by discussion and consensus, with the involvement of a third au-
thor or amethodologist where appropriate.We contacted the orig-
inal study authors for clarification or for missing data whenever
possible. If differences were found between publications of a study,
we contacted the original authors for clarification. We used data
from the main paper(s) if no further information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• presence or absence of nasal polyps;
• polyp score (where applicable);
• whether the patient has had previous sinus surgery.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we planned
to convert into binary data.
We prespecified the time points of interest for the outcomes in
this review. While studies may have reported data at multiple time
points, we only extracted the longest available data within the time
points of interest. For example, for ’short’ follow-up periods, our
time pointwas defined as ’three to sixmonths’ post-randomisation.
If a study had reported data at three, four and six months, we only
extracted and analysed the data for the six-month follow-up.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. We followed the guidance in the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011), and
we used theCochrane ’Risk of bias’ tool.With this tool we assessed
the risk of bias as ’low’, ’high’ or ’unclear’ for each of the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
We summarised the effects of dichotomous outcomes (e.g. propor-
tion of patients with symptom resolution) as risk ratios (RR) with
CIs. For the key outcomes that we presented in the ’Summary of
findings’ table, we also expressed the results as absolute numbers
based on the pooled results and compared to the assumed risk. We
also planned to calculate the number needed to treat to benefit
(NNTB) using the pooled results. The assumed baseline risk is
typically either (a) the median of the risks of the control groups
in the included studies, this being used to represent a ’medium
risk population’ or, alternatively, (b) the average risk of the control
groups in the included studies is used as the ’study population’
(Handbook 2011). If a large number of studies were available,
and where appropriate, we also planned to present additional data
based on the assumed baseline risk in (c) a low-risk population
and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD) or as standardised
meandifference (SMD) if different scales had beenused tomeasure
the same outcome. We provided a clinical interpretation of the
SMD values.
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
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If we had found cluster-randomised trials, we would have analysed
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We tried to contact study authors via email whenever the outcome
of interest was not reported, if the methods of the study suggested
that the outcome had been measured. We did the same if not all
data required for meta-analysis had been reported, unless themiss-
ing data were standard deviations. If standard deviation data were
not available, we approximated these using the standard estima-
tion methods from P values, standard errors or 95% CIs if these
were reported as detailed in the Cochrane Handbook for Systematic
Reviews of Interventions (Handbook 2011). If it was impossible to
estimate these, we contacted the study authors.
Apart from imputations for missing standard deviations, we con-
ducted no other imputations. We extracted and analysed all data
using the available case analysis method.
Imputing total symptom scores
Where a paper did not present information for the total dis-
ease severity in terms of patient-reported symptom scores but did
present data for the results of individual symptoms, we used the
symptoms covering the important domains of the EPOS chronic
rhinosinusitis diagnosis criteria (EPOS 2012) to calculate a total
symptom score. The EPOS 2012 criteria for chronic rhinosinusitis
require at least two symptoms. One of the symptoms must be ei-
ther nasal blockage or nasal discharge; other symptoms can include
facial pressure/pain, loss of sense of smell (for adults) or cough (for
children). Where mean final values or changes from baseline were
presented in the paper for the individual symptoms we summed
these to calculate a ’total symptom score’. We calculated standard
deviations for the total symptom score as if the symptoms were in-
dependent, random variables that were normally distributed. We
acknowledge that there is likely to be a degree of correlation be-
tween the individual symptoms, however we used this process be-
cause the magnitude of correlation between the individual symp-
toms is not currently well understood (no evidence found). If the
correlation is high, the summation of variables as discrete vari-
ables is likely to give a conservative estimate of the total variance
of the summed final score. If the correlation is low, this method
of calculation will underestimate the standard deviation of the to-
tal score. However, the average patient-reported symptom scores
have a correlation coefficient of about 0.5; if this is also applica-
ble to chronic rhinosinusitis symptoms, the method used should
have minimal impact (Balk 2012). As this method of calculation
does not take into account weighting of different symptoms (no
evidence found), we downgraded all the disease severity outcomes
for lack of use of validated scales whenever this occurred.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We assessed statistical heterogeneity by visually inspecting the for-
est plots and by considering the Chi² test (with a significance level
set at P value < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results are mentioned but not reported adequately in a
way that allows analysis (e.g. the report only mentions whether the
results were statistically significant or not), bias in a meta-analysis
is likely to occur. We sought further information from the study
authors. If no further information could be found, we noted this
as being a ’high’ risk of bias. Quite often there was insufficient
information to judge the risk of bias; we noted this as an ’unclear’
risk of bias (Handbook 2011).
Publication bias (between-study reporting bias)
We planned to assess funnel plots if sufficient trials (more than 10)
were available for an outcome. If we had observed asymmetry of the
funnel plot, we would have conducted more formal investigation
using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we planned to analyse
treatment differences as a risk ratio (RR) calculated using theMan-
tel-Haenszel methods. We will analyse time-to-event data using
the generic inverse variance method.
For continuous outcomes, if all the data were from the same scale,
we planned to poolmean values obtained at follow-upwith change
outcomes and report this as a MD. However, if the SMD had to
be used as an effect measure, we did not plan to pool change and
endpoint data.
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When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
We planned to conduct some subgroup analyses regardless of
whether statistical heterogeneity was observed, as these are widely
suspected to be potential effect modifiers. For this review, this in-
cluded:
• phenotype of patients: whether patients have chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, a mixed group or the status of polyps is not known
or not reported. We planned this subgroup analysis as although
there appears to be a considerable overlap between the two forms
of chronic rhinosinusitis with regards to inflammatory profile,
clinical presentation and effect of treatment (Cho 2012;
DeMarcantonio 2011; Ebbens 2010; Fokkens 2007; Ragab
2004; Ragab 2010; van Drunen 2009), there is some evidence
pointing to differences in the respective inflammatory profiles
(Kern 2008; Keswani 2012; Tan 2011; Tomassen 2011; Zhang
2008; Zhang 2009), and potentially even differences in
treatment outcome (Ebbens 2011).
We presented the main analyses of this review according to the
subgroups of phenotypes of chronic rhinosinusitis. We presented
all other subgroup analysis results in tables.
When studies had amixed group of patients, we analysed the study
as one of the subgroups (rather than as a mixed group) if more
than 80% of patients belonged to one category. For example, if
81% of patients had chronic rhinosinusitis without nasal polyps,
we analysed the study as that subgroup.
In addition to the subgroups above, we planned to conduct the
following subgroup analyses in the presence of statistical hetero-
geneity for the relevant comparisons:
• patient age (children versus adults);
• dose;
• duration of treatment;
• method of delivery.
Sensitivity analysis
We planned to carry out sensitivity analyses to determine whether
the findings were robust to the decisions made in the course of
identifying, screening and analysing the trials. We planned to con-
duct sensitivity analysis for the following factors, whenever possi-
ble:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we defined these as studies that have a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed);
• how outcomes were measured: we planned to investigate
the impact of including data where the validity of the
measurement is unclear.
If any of these investigations found a difference in the size of
the effect or heterogeneity, we mentioned this in the Effects of
interventions section.
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality
of evidence for each outcome using the GDT tool (http://
www.guidelinedevelopment.org/) for the main comparison pairs
listed in the Types of interventions section. The quality of evi-
dence reflects the extent to which we are confident that an esti-
mate of effect is correct and we applied this in the interpretation
of results. There are four possible ratings: ’high’, ’moderate’, ’low’
and ’very low’. A rating of ’high’ quality evidence implies that we
are confident in our estimate of effect and that further research is
very unlikely to change our confidence in the estimate of effect.
A rating of ’very low’ quality implies that any estimate of effect
obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ table presents only the seven top prior-
ity outcomes (disease-specific health-related quality of life, disease
severity score, adverse effects and generic quality of life score). We
did not include the outcomes of endoscopic score and CT scan
score in the ’Summary of findings’ table.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 2470 references after removal of
duplicates. We screened titles and abstracts and subsequently re-
moved 2429 references. We assessed 41 full texts for eligibility.
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We excluded 18 studies (21 references), with reasons. We included
nine studies (13 references). We identified three ongoing studies.
There are four studies awaiting assessment because we cannot lo-
cate the full-text papers.
A flow chart of study retrieval and selection is provided in Figure
1.
12Different types of intranasal steroids for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Process for sifting search results and selecting studies for inclusion.
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Included studies
Design
All studies included were randomised trials andmost were double-
blinded (in two studies blinding was not stated).
Sample sizes
The studies included ranged in size from small studies with as few
as 20 patients in the treatment arms of interest (Lund 1998), to
much larger studies, which included over 200 participants (Small
2005; Stjarne 2006).
Setting
All studies were conducted in a secondary or tertiary care setting
and in various international locations, including three Scandina-
vian studies. It was notable that there were no studies from the
Asian continent.
Participants
The participants in all but one study were adults ranging from 18
to 86 years old; the one paediatric study had an age range of 6
to 17. The adult participants in all but one study were predomi-
nantly male (range 72% to 79%), with one study including only
38% male participants. In all studies the participants had chronic
rhinosinusitis with nasal polyps with visible polyps on nasal ex-
amination. There were no studies including patients with chronic
rhinosinusitis without nasal polyps.
Interventions
The details of the interventions are shown in Table 1 under the fol-
lowing headings: comparison of different steroid molecules (three
studies), high-dose versus low-dose (five studies), twice daily versus
once daily and different delivery methods (one study). All studies
had a placebo arm, except one (Demirel 2008).
Intranasal steroid formulations included were fluticasone propi-
onate, beclomethasone dipropionate, mometasone furoate and
budesonide (see below).
Summary of studies comparing different steroid molecules
Study ID Polyps status Intervention Comparison Delivery
method
Daily dose Dosing regime Treatment
time
Filipovic 2006 Bilateral poly-
posis
in asthma pa-
tients
Fluticasone
propionate
Mometasone
furoate
Nasal spray 200 µg Once daily 3 months
Holmberg
1997
Bilateral
polyps (polyp
score 1 or 2)
Fluticasone
propionate
Beclometha-
sone dipropi-
onate
Nasal spray 400 µg Twice daily 26 weeks
Lund 1998 Bilateral nasal
polyposis
requiring sur-
gical interven-
tion
Fluticasone
propionate
Beclometha-
sone dipropi-
onate
Nasal spray 400 µg Twice daily 12 weeks
Summary of studies comparing high-dose versus low-dose
steroids
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Study ID Polyps sta-
tus
Drug Delivery
method
Daily dose
(Interven-
tion)
Regimen Daily dose
(Compari-
son)
Regime Duration of
treatment
Chur 2013 Bilateral Mometa-
sone furoate
Nasal spray 200 µg (6
to 11 years)
; 400 µg (12
to 18 years)
Twice daily 100 µg (6
to 11 years)
; 200 µg (12
to 18 years)
Once daily 4 months
Small 2005 Bi-
lateral, clini-
cally signifi-
cant conges-
tion/
obstruction
Mometa-
sone furoate
Nasal spray 400 µg Twice daily 200 µg Once daily 4 months
Stjarne 2006 Bi-
lateral, clini-
cally signifi-
cant conges-
tion/
obstruction
Mometa-
sone furoate
Nasal spray 400 µg Twice daily 200 µg Once daily 4 months
Penttila
2000
Bi-
lateral mild
or moderate
nasal poly-
posis
Fluticasone
propionate
Nasal drops 800 µg Twice daily 400 µg Once daily 12 weeks
Demirel
2008
Bilateral Fluticasone
propionate
Nasal drops 800 µg Twice daily 400 µg Once daily 12 weeks
Summary of studies comparing different delivery methods
Study ID Polyps
status
Drug Method Daily
dose
Regime Drug Method Daily
dose
Regime Duration
Johansen
1993 Eosinophilic
nasal
polyposis
with
polyp
scores of
2 or less
on each
side
Budes-
onide
Aque-
ous nasal
spray
400 µg Twice
daily
Budes-
onide
Aerosol 400 µg Twice
daily
3 months
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Outcomes
Only one study included a disease-specific health-related quality
of life (HRQL) tool for outcome assessment and only three stud-
ies included an assessment of overall disease severity. Nasal ob-
struction and loss of sense of smell as individual symptoms were
assessed in all studies but other chronic rhinosinusitis symptoms
were variably and inconsistently checked. No studies included
generic HRQL tools. Endoscopic grading of polyps was reported
in all studies. Adverse events were reported in all but one study
(Demirel 2008). Epistaxis, which is an outcome of interest of this
review, was defined to include a wide range of bleeding episodes,
from frank bleeding to bloody nasal discharge to flecks of blood in
the mucus in two studies (Small 2005; Stjarne 2006). The other
studies did not provide a definition of epistaxis, but would have
been likely to include non-severe episodes since very few of the
withdrawals were related to epistaxis.
Funding and conflict of interest
All of the studies (except Demirel 2008 and Filipovic 2006, which
did not provide any information on funding or conflicts of inter-
est) were either directly funded by pharmaceutical companies that
manufacture one or more of the interventions compared, finan-
cially supported by industry including the companies (GlaxoWell-
come, Schering Plough, Astra and Merck Sharpe and Dohme), or
had authors who were employees or recipients of other types of
funding from the companies.
Excluded studies
We excluded 17 papers after reviewing the full text. Further details
for the reasons for exclusion can be found in the Characteristics
of excluded studies table. Ten of the studies were clinical trials that
made a comparison relevant to this review but we excluded them
due to the duration of the treatment not meeting the inclusion cri-
terion of 12 weeks. Five of these treated and followed up patients
for one month or less (Lildholdt 1995; NCT01405339; Reychler
2015; Toft 1982; Wang 2012), and four treated and followed up
patients for between six and eight weeks (Filiaci 2000; Jankowski
2001; Raghavan 2006; Tos 1998). The remaining study compared
betamethasone with fluticasone propionate with a treatment du-
ration of eight weeks, although the follow-up time was 12 weeks
(Fowler 2002).
We excluded five studies due to the included population. In four
of these papers all patients underwent sinus surgery either imme-
diately before the trial started or during the trial (Bross-Soriano
2004; Dijkstra 2004; NCT02194062; Singhal 2008). We ex-
cluded the other study due to the population: it stated that the
participants had allergic or non-allergic chronic rhinosinusitis, but
on closer inspection of the inclusion criteria we thought that it
included only people with allergic or non-allergic rhinitis (Giger
2003).
Of the remaining two studies, one was a clinical trial register record
of a study that was going to compare two different delivery meth-
ods (aerosol versus spray) but the study authors confirmed that
the trial had not been completed or published (NCT00788463).
The reason for early termination was not provided. The other was
a study looking at the optimal method for delivery of intranasal
spray, which studied the distribution of dye at five sinonasal sites
(Cannady 2005).
Ongoing studies
We identified three relevant ongoing studies, all of which
are in adults with chronic rhinosinusitis with nasal polyps
(NCT01622569;NCT01624662;NCT01946711). Two of these
are large, multicentre trials each with a planned population of over
300 patients (NCT01622569; NCT01624662). These two trials
will make the same comparisons, comparing three different doses
of fluticasone proportionate (400 µg bid, 200 µg bid and 100 µg
bid) with placebo. All of the arms will use a novel bi-directional
device. The studies were completed in October 2015 but no study
data were available at the time of writing. The other trial com-
pares two deliverymethods for budesonide (inhalation versus nasal
spray) (NCT01946711). We contacted the investigators and they
reported that the trial should be completed during 2016.
Risk of bias in included studies
See Figure 2 for the ’Risk of bias’ graph (our judgements about
each risk of bias item presented as percentages across all included
studies) and Figure 3 for the ’Risk of bias’ summary (our judge-
ments about each risk of bias item for each included study).
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
Three of the included studies provided a description that suggested
that adequate sequence generation was conducted (Chur 2013;
Lund 1998; Stjarne 2006). Another three stated that the trials
were randomised but did not provide further information, making
them at an ’unclear’ risk of bias (Filipovic 2006; Holmberg 1997;
Johansen 1993). Penttila 2000 and Small 2005 also did not pro-
vide details of randomisation. However, these studies were con-
ducted fairly recently as multinational trials, and therefore should
have sufficient methodology and resources to ensure that adequate
sequence generation procedures were carried out. We rated these
as low risk of bias.
Another study stated that patients were “randomly divided”
(Demirel 2008). However, we rated this study as high risk of bias
because the baseline risks, particularly the age of the participants,
were not balanced between the groups. It was also a very small
study, with 11 participants randomised to the once daily group
and 15 to the twice daily group.
Allocation concealment
None of the studies described how allocation concealment was
carried out, so we judged them all as unclear risk of bias. How-
ever, Penttila 2000, Small 2005 and Stjarne 2006 are large multi-
national trials, which should have adequate sequence generation,
adequate blinding and no other factors suggesting that allocation
concealment could be compromised. We considered these to have
low risk of bias. Although Chur 2013 also had adequate sequence
generation, it used blocked randomisation with unclear effective-
ness of blinding and therefore it is unclear whether allocation con-
cealment was well maintained.
Blinding
The ratings for the risk of performance bias versus detection bias
were very well correlated for this review.
Most of the outcomes were assessed by patients and the overall
risks of bias were low when both participants and investigators
were adequately blinded. We did not find information suggesting
that the clinicians could have obtained extra information from
blood tests etc. to ’guess’ the which treatment the patients were
allocated to.
One study was an abstract and stated that it was a single-blinded
study but did not provide information on who was blinded
(Filipovic 2006). However, since the study compared different
drugs with the same delivery method (nasal spray) and dosing
schedule (once daily), we rated this as unclear risk of bias rather
than high risk.
All the other eight studies described using a “double blinded”
design their report. However, we only considered the risk of both
performance and detection bias to be low for five of the studies,
with adequate measures to mask the type of treatment given (
Holmberg 1997; Lund 1998; Penttila 2000; Small 2005; Stjarne
2006).
We rated blinding as inadequate (high risk of bias) in three stud-
ies, despite their being reported as ’double-blinded’ studies (Chur
2013; Demirel 2008; Johansen 1993). The blinding was inade-
quate in these studies, as there was no placebo or ’dummy’ used
to account for differences in the number of times treatment was
administered or methods of delivery. In Chur 2013, participants
“receivedMFNS 200 mcg once daily, MFNS 200 mcg twice daily,
placebo once daily, or placebo twice daily”, instead of using a
double-dummy design, where all participants received the medi-
cation twice daily (with a placebo given for those who had once
daily treatment); groups either hadmedication once or twice daily.
Therefore, there was no blinding of participants in terms of know-
ing whether they were on the once daily or twice daily regimen.
Similarly, Johansen 1993 stated that “The patients were treated
with either budesonide aqua (Rhinocort Aqua) or budesonide
aerosol (Rhinocort Aerosol), 50 mcg x 2 in each nostril, twice
daily = 400 mcg/day or placebo (aqua) or aerosol).” Whilst there
may be adequate blinding for treatment versus placebo, there is
no blinding when comparing different dosage forms.
Although Demirel 2008 claimed to be double-blinded, the inter-
ventions were given in a different format (nasal spray versus nasal
drops) and at different frequencies (one versus two times per day),
so it is difficult to see how either the personnel or participants were
blind to the intervention. There was no mention of a placebo.
Incomplete outcome data
The risk of attrition bias was unclear in seven of the included
studies (Chur 2013; Demirel 2008; Filipovic 2006; Johansen
1993; Penttila 2000; Small 2005; Stjarne 2006). These studies did
not provide enough information to adequately judge the risk. For
example, Johansen 1993 reported that 5/91 (5.5%) participants
did not complete the study. There is no information on howmany
were randomised to each group in Johansen 1993, so it is difficult
to determine whether this could have affected the results.
In two studies that were three-arm trials including a placebo group
(Small 2005; Stjarne 2006), we considered the overall risk of attri-
tion bias to be high due to imbalances in the proportion of drop-
outs between the active and placebo groups. However, the drop-
out rates for the active intervention groups, which are of interest in
this review, were similar and we still considered them acceptable.
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Therefore we considered these studies as being at an unclear risk
of attrition bias for this review, but at a high risk for our accom-
panying review, which assesses intranasal steroids versus placebo
(Chong 2016a).
We rated the risk of attrition bias as high for two studies. Lund
1998 only included 10 participants in each of the fluticasone
and beclomethasone groups. Three patients dropped out from
the fluticasone group (70%), but none dropped out from the
beclomethasone group. This study carried out last observed car-
ried forward observation (LOCF) for the missing outcomes. In
Holmberg 1997, the number of participants who dropped out was
twice as high in one group (4/19 in the fluticasone propionate
group and 2/18 in the beclomethasone propionate group).
Selective reporting
Many of the study reports only presented effectiveness outcomes
in graphs and only provided limited, selective information, for
example P values or mean values when statistical significance was
noted. Since many of the effectiveness outcomes did not show a
significant difference between the intervention and comparison
groups in this review (i.e. there were no noticeable differences
between the different types of corticosteroids, methods of delivery,
doses or number of administrations per day), we are uncertain
whether this lack of detail in reporting is related to the lack of
’positive’ results.
We considered only one study to be at low risk of bias, as all
expected outcomes were reported (Small 2005).
We considered the risk of selective reporting bias to be high in
four studies (Chur 2013; Demirel 2008; Holmberg 1997; Lund
1998).
Two studies reported the use of diaries for patients to record symp-
toms (Holmberg 1997; Lund 1998). However, neither study pro-
vided information on how the collected data would be analysed
and the results were subsequently presented in a variety of ways
with different cut-off points, where it is not clear why they were
selected.
The primary endpoint in Chur 2013 was “safety” (cortisol levels)
and despite presenting the mean change values for effectiveness
outcomes, they did not provide any information on P values or
standard deviations. The study authors’ rationale for collecting but
not fully reporting the data was: “No statistical analysis of efficacy
end points was pre-specified in the study protocol, and only de-
scriptive efficacy statistics were collected.” We observed that these
values (mean changes) were similar between groups and unlikely
to be statistically significant, so poor reporting due to lack of ben-
eficial effects cannot be ruled out. Similarly, Demirel 2008 mainly
reported outcomes in graphs and did not provide information on
standard deviations and P values, which are necessary for meta-
analysis.
We considered the remaining three studies to be at unclear risk.
Therewas not enough information in themethods and/or protocol
and we found it difficult to judge whether there was a risk of
reporting bias (Filipovic 2006; Johansen 1993; Penttila 2000).
Other potential sources of bias
Use of validated outcome measures
The lack of use of validated outcome measures is a major concern
in terms of bias. If an instrument is insensitive for measuring
differences, this biases towards a finding of ’no difference’ in the
studies and also in this review.
None of the included studies mentioned using validated out-
comemeasures, for either of the primary outcomes of effectiveness
(disease-specific health-related quality of life and disease severity/
symptom scores). Of the studies that attempted to use patient
diaries or questionnaires to measure severity, most used a 0 to 3
scale. There is no evidence that this scale, especially when used
as a single scale, has the sensitivity to distinguish between groups
of patients who improved versus those who did not improve (dis-
criminant validity). None of the studies attempted to assess all of
the four symptoms used to define chronic rhinosinusitis that are
mentioned in EPOS 2012 (nasal blockage, rhinorrhoea/rhinitis,
loss of sense of smell and facial pain (adults)/cough (children)).
Facial pain was not measured by most studies.
The scales used to measure nasal polyps were generally well de-
scribed. However, again it is unclear whether a 0 to 3 scale is has
the discriminant validity to detect a difference in these small trials.
Effects of interventions
See: Summary of findings for the main comparison
Different types of intranasal corticosteroid molecules for chronic
rhinosinusitis; Summary of findings 2High-dose versus low-dose
intranasal corticosteroids for chronic rhinosinusitis
Where the range of scales and values for minimal important
differences were unclear, we used the standardised mean dif-
ference (SMD) to estimate the effect sizes. As suggested in
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), we used standard rules of thumb in the inter-
pretation of effect sizes (SMD, or Cohen’s effect size of < 0.41 =
small, 0.40 to 0.70 = moderate, > 0.70 = large) (Cohen 1988).
Comparison 1: Different type of corticosteroids:
fluticasone propionate versus beclomethasone
dipropionate
We found two studies in participants with bilateral polyps (a
combined sample size of 56) comparing fluticasone propionate
aqueous nasal spray (FPANS) versus beclomethasone dipropionate
aqueous nasal spray (BDANS) at a daily dose of 400 µg, delivered
using nasal sprays twice a day. However, the results were poorly
reported and there was insufficient information to conduct any
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pooling of data (Holmberg 1997; Lund 1998). The follow-up was
26 weeks for Holmberg 1997 and 12 weeks for Lund 1998.
Primary outcomes
Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20
Neither Holmberg 1997 nor Lund 1998 mentioned measuring
quality of life.
Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS)
questionnaire and visual analogue scales)
Neither of the studies provided patient-reported total symptoms
score results using an instrument validated in a chronic rhinosi-
nusitis population. Both studies included information about mea-
suring a patient-reported symptom score in their methods section,
but did not report much information at all about these. Instead,
some form of physician-rated scores were reported.
InHolmberg 1997, themethods sectiondescribed patients record-
ing the following symptoms on daily record cards: nasal block-
age on waking in the morning, nasal blockage during the rest of
the day, sense of smell and rhinorrhoea. The outcomes were re-
ported on a four-point scale (0 to 3, 0 = no symptoms, 3 = severe
symptoms). These were not well reported in the results. Instead,
they reported “physician’s assessment of symptoms”, which was
not mentioned in the methods section or defined anywhere else
in the paper.
The methods section of Lund 1998 reported that patients were
issued with daily record cards to assess nasal blockage, sense of
smell, degree of nasal discomfort (facial pain and headache) and
overall rhinitis symptoms (sneezing, rhinorrhoea, nasal itching) on
a five-point rating scale (0 to 4). However, the results section only
reported percentage of days with “no nasal blockage during the
day” (“...trend for FPANS to be more effective”) and percentage
of days with “no rhinitis symptoms in the day” (a median value
of 89% and 96% for FPANS-treated and BDANS-treated groups,
respectively, at week 12).
Significant adverse effect: epistaxis
Holmberg 1997 reported that “Adverse events were reported in 14
patients (78%) receiving placebo, 13 patients (68%) receiving flu-
ticasone propionate aqueous nasal spray, and 16 patients (89%) re-
ceiving beclomethasone dipropionate aqueous nasal spray”. How-
ever, they mentioned that “The only predictable adverse event
considered drug related was epistaxis”. No specific figures were
provided.
Lund 1998 reported that “There were more adverse events (7
[70%]) reported in the FPANS-treated group comparedwith those
(3 [33%]) in the group receiving placebo and in the BDANS-
treated group (3 [30%]).” There was no information about
whether any of these events were epistaxis.
Secondary outcomes
Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
Neither Holmberg 1997 nor Lund 1998 mentioned measuring
quality of life.
Other adverse effects: local irritation (including nasal
irritation, oral thrush, sore throat)
Lund 1998 reported that there was “1 predictable adverse event -
throat irritation - in the FPANS-treated group” (1 in 10 patients).
It is unclear whether any other events reported by the 10 patients
with adverse effects (seven in the fluticasone group, three in the
budesonide group) were related to other forms of local irritation.
Other adverse effects, such as stunted growth in children and
osteoporosis in adults (minimum time point: six months of
treatment and follow-up)
Although Holmberg 1997 followed up patients for six months,
this outcome was not reported.
Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-
Kennedy/Lund-Mackay)
Lund 1998 reported that the median total polyps score (range 0 to
6) was 2 in the fluticasone group and 2.5 in the beclomethasone
group, with a reported P value of 0.66. However, this included
values from patients who had dropped out from the study (3/10
in the fluticasone group) and was imputed using a last observation
carried forward (LOCF) method.
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
A CT scan was conducted at baseline to determine eligibility in
Lund 1998 but was not reported as an outcome.
The quality of the evidence is very low (GRADE) for all out-
comes in this comparison. See Summary of findings for the main
comparison.
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Comparison 2: Different types of corticosteroids:
fluticasone propionate versus mometasone furoate
We only found one abstract for a study that compared fluticasone
propionate versusmometasone furoate, 200 µg, administered once
daily as an aqueous spray (Filipovic 2006).
The abstract only mentioned that “both drugs produced statisti-
cally significant reductions” (P value < 0.01) in nasal obstruction,
postnasal drip, anterior rhinorrhoea and an improvement, which
is presumably compared to baseline. The study also stated that
“no statistically significant differences were observed between the
two drugs for most evaluated parameters”.
The study reported that both drugs were “well tolerated” without
providing any further information.
The quality of the evidence is very low (GRADE) for all out-
comes in this comparison. See Summary of findings for the main
comparison.
Comparison 3: High-dose versus low-dose intranasal
steroids
There were five studies, with a total of 663 participants in the
intervention arms, which compared a higher dose of intranasal
corticosteroids (administered twice a day) versus a lower dose (ad-
ministered once a day) (Chur 2013; Demirel 2008; Penttila 2000;
Small 2005; Stjarne 2006). One of these was in children aged be-
tween 6 and 18 years (Chur 2013).
Study ID Polyps sta-
tus
Drug Delivery
method
Daily dose
(Interven-
tion)
Regime Daily dose
(Compari-
son)
Regime Duration of
treatment
Chur 2013 Bilateral Mometa-
sone furoate
Nasal spray 200 µg (6
to 11 years)
; 400 µg (12
to 18 years)
Twice daily 100 µg (6 to
11 years)
200 µg (12
to 18 years)
Once daily 4 months
Small 2005 Bi-
lateral, clini-
cally signifi-
cant conges-
tion/
obstruction
Mometa-
sone furoate
Nasal spray 400 µg Twice daily 200 µg Once daily 4 months
Stjarne 2006 Bi-
lateral, clini-
cally signifi-
cant conges-
tion/
obstruction
Mometa-
sone furoate
Nasal spray 400 µg Twice daily 200 µg Once daily 4 months
Penttila
2000
Bi-
lateral mild
or moderate
nasal poly-
posis
Fluticasone
propionate
Nasal drops 800 µg Twice daily 400 µg Once daily 12 weeks
Demirel
2008
Bilateral Fluticasone
propionate
Nasal drops 800 µg Twice daily 400 µg Once daily 12 weeks
Primary outcomes
Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
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Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20
None of the studies mentioned measuring quality of life.
Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS)
questionnaire and visual analogue scales)
None of the papers provided results for a patient-reported total
symptoms score using an instrument validated in a chronic rhi-
nosinusitis population. Where available, we combined the results
for the individual symptoms into a total score according to the
methods set out in Dealing with missing data. In order to be in-
cluded in the analysis the results had to at least meet the EPOS
2012 diagnostic criteria, which requires at least two symptoms,
one of which must be nasal blockage/obstruction/congestion or
nasal discharge (anterior/posterior nasal drip) with the other pos-
sible symptoms being facial pressure/pain, loss of sense of smell
(adults) or cough (children).
Three studies reported results for individual symptoms but the
results were presented in different ways making analysis difficult (
Chur 2013; Small 2005; Stjarne 2006). The remaining two studies
only recorded clinician-rated symptoms so this information has
not been presented (Demirel 2008; Penttila 2000).
Chur 2013 measured and partially reported some data for the in-
dividual symptoms of nasal congestion/obstruction, anterior rhi-
norrhoea/postnasal drip and loss of sense of smell. The symptoms
were reported by participants (with the assistance of a parent or
guardian if needed) and scored on a 0- to 4-point scale. These re-
sults were presented as mean change from baseline at four months.
The paper did not present standard deviations or P values for the
results, the rationale for which was that the study’s primary out-
come was safety and they had not specified in the protocol that
the effectiveness results would be analysed. However, with a mean
difference of change of 0.1 points, it is unlikely that there is an
important difference between the groups either clinically or sta-
tistically (see results presented below).
Small 2005 and Stjarne 2006 both asked participants to score the
symptoms nasal congestion/obstruction, loss of sense of smell and
anterior rhinorrhoea on a four-point scale. The results were pre-
sented separately in graphs as the change from baseline values. P
values for the between-group differences were only given for some
comparison pairs to denote the level of statistical significance, for
example “P < 0.05”, “P < 0.01” etc. There was sufficient informa-
tion to impute standard deviations based on these values for nasal
blockage and rhinorrhoea for both studies. However, there was no
statistically significant difference between the groups for loss of
sense of smell in Stjarne 2006 and no P values were reported.
Overall symptom scores
None of the studies provided enough information to enable the
calculation of an overall symptom score for all four groups of
symptoms used for the definition of chronic rhinosinusitis in
EPOS 2012.
Only one study provided enough information to estimate a total
score based on three of the four EPOS domains used for definition
of chronic rhinosinusitis in EPOS 2012 (Small 2005). This study
provided enough information to calculate the average score for
nasal blockage, rhinorrhoea and loss of sense of smell. Although
Stjarne 2006 also measured all of the same symptoms, it did not
report the P values or standard deviations for loss of sense of smell
because the results were not statistically different. Therefore, these
results could only be used to measure an average symptom score
based on two domains (nasal blockage and rhinorrhoea). The fol-
lowing are the pooled results:
• Average combined score for three EPOS 2012 domains
(nasal blockage, rhinorrhoea, loss of sense of smell): the mean
difference (MD) was -0.13 (95% confidence interval (CI) -0.37
to 0.11; 237 participants; one study) on a 0 to 3 scale. It is a very
small effect size and is not likely to be a clinically important
difference (Analysis 1.1).
• Average combined score for two EPOS 2012 domains
(nasal blockage, rhinorrhoea): the MD was -0.19 (95% CI -0.36
to -0.02; 441 participants; two studies; I2 = 0%) on a 0 to 3
scale, favouring the high-dose group. However, it is a very small
effect size and this may not be a clinically important difference
(Analysis 1.1).
These results have to be interpreted carefully because the studies
only appeared to present their results in sufficient detail for further
analysis when they showed a statistically significant improvement
compared to placebo, therefore biasing the results towards a posi-
tive finding.
Individual symptom scores
Chur 2013 analysed the mean change from baseline for 51 partic-
ipants in the high-dose group and 50 participants in the low-dose
group. The mean change (recorded on a 0- to 4-point scale) and
percentage change compared to baseline values are shown below.
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Symptoms Mean (%) change from baseline on a 0- to 4-point scale
High-dose group Low-dose group
Nasal congestion -0.99 (-49%) -0.91 (-38%)
Rhinorrhoea -0.73 (-38%) -0.70 (-43%)
Loss of sense of smell -0.53 (-43%) -0.55 (-49%)
Small 2005 and Stjarne 2006 presentedmean differences (MD) in
the change from baseline symptom score between the high-dose
and low-dose groups at four months, on a 0- to 3-point scale. (We
used these values to calculate the overall symptom scores above).
Negative values show that there is a greater decrease in severity in
the high-dose (twice daily) group.
• Nasal congestion: MD -0.24 (95% CI -0.39 to -0.08; 441
participants; two studies; I2 = 0%); there is a slightly larger
reduction (small effect size) in nasal blockage in the high-dose
group.
• Rhinorrhoea: MD -0.15 (95% CI -0.33 to 0.03; 441
participants; two studies; I2 = 0%); there is similar reduction in
rhinorrhoea in both groups.
• Loss of sense of smell: MD 0.06 (95% CI -0.20 to 0.32;
237 participants; one study); there is similar reduction in loss of
sense of smell in both groups in Small 2005, but no statistically
significant reduction in Stjarne 2006 (-0.40 versus -0.33, MD -
0.07) (see Analysis 1.2).
The quality of the evidence is very low (GRADE) for the measures
of disease severity. See Summary of findings 2.
Significant adverse effect: epistaxis
There was an increased risk of epistaxis in the high-dose group
(risk ratio (RR) 2.06, 95% CI 1.20 to 3.54; 637 participants; four
studies; I2 = 0%) (Analysis 1.3).
Two of the four studies, which had the most weight in the pooled
results, defined epistaxis to include a wide range of bleeding
episodes, from frank bleeding to bloody nasal discharge to flecks
of blood in the mucus (Small 2005; Stjarne 2006). Chur 2013
did not provide a definition but there is a high chance that they
also used similar definitions to the other two studies, since this
series of studies shared many common points in their protocols.
The fourth study also did not provide a definition, but of the eight
events reported, only one required a withdrawal (Penttila 2000).
The quality of the evidence is moderate (GRADE) for this com-
parison. See Summary of findings 2.
Secondary outcomes
Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
None of the studies mentioned measuring quality of life.
Other adverse effects: local irritation (including nasal
irritation, oral thrush, sore throat)
Similar numbers of patients experienced local irritation in both
groups (RR 0.97, 95% CI 0.28 to 3.31; 542 participants; three
studies; I2 = 0%) (Analysis 1.4), in the studies where these results
could be analysed (Chur 2013; Small 2005; Stjarne 2006). How-
ever, the total number of events we have included in the analy-
sis is an underestimation of the frequency of local irritation; the
studies all used different descriptions (such as nasal burning, nasal
dryness, nasal irritation and throat irritation) and we could only
choose the most frequent type of local irritation for each study in
the analysis to prevent double-counting.
Other adverse effects, such as stunted growth in children and
osteoporosis in adults (minimum time point: six months of
treatment and follow-up)
All the studies followed up participants for about four months.
This was not long enough to provide a reliable measure of the
longer-term adverse effects and none of the studies reported these.
Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-
Kennedy/Lund-Mackay)
Small 2005 reported themean change frombaseline innasal polyps
score (0 to 3 range). The MD was 0.19 (95% CI -0.16 to 0.54;
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237 participants) favouring the once daily group (Analysis 1.5).
However, this difference is unlikely to be of clinical significance.
Stjarne 2006 did not find a statistically significant difference in
polyps size between the low-dose group and the placebo arms and
therefore did not provide any P values to allow for the estimation
of standard deviations. The polyps score (0 to 3 range) decreased
by 0.96 points in the high-dose group and 0.78 points in the low-
dose group. A mean difference of 0.18 between the two groups
on a four-point scale has no clinical significance, especially as the
correlation between polyp size and symptoms is poor.
Chur 2013 reported that polyps size, measured on a four-point
scale (0 to 3) decreased by 1.1 points (-34%) compared to baseline
in the high-dose group (n = 51) and by 0.92 points (-26%) in the
low-dose group (n = 50). Standard deviations and P values were
not provided, therefore it is not possible to estimate the statistical
significance of this difference. As in Stjarne 2006, a mean differ-
ence of 0.18 between the two groups on a four-point scale has no
clinical significance, especially as the correlation between polyp
size and symptoms is poor.
Demirel 2008 investigated fluticasone propionate nose drops and
reported a decrease of 0.84 points (54%) compared to baseline
in the twice daily (800 µg/day) group (n = 13), as opposed to
a decrease of 0.9 points (40%) in the once daily (400 µg/day)
group (n = 10). This is unlikely to represent a clinically significant
reduction, since the baseline scores differed by about 0.7 points
on a scale of 0 to 3 and the sample sizes are very small.
Penttila 2000 reported the “percentage of patients showing im-
provement” (it is unclear how this was defined). The risk ratio for
“improvement” was 1.71 (95% CI 0.91 to 3.21; 92 participants)
at 12 weeks for patients in the high-dose group (Analysis 1.6).
Overall, all five studies reported some decrease in polyps score in
the high-dose group, but the clinical significance of this is unclear.
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
There was no mention that CT scans were conducted at follow-
up in any of the studies.
Comparison 4: Different types of delivery methods:
aqueous nasal spray versus aerosol spray
One study compared two methods (aqueous nasal spray versus
aerosol spray) of delivering 400 µg of budesonide per day, given
as two divided doses (morning and night) for three months in
patients who had eosinophilic nasal polyposis with polyp scores of
2 or less on each side (Johansen 1993). This study reported ran-
domising 91 patients into three groups and 86 completed. How-
ever, the numbers in each group were not reported.
The study presented the results in graphs and not much further
information was provided to allow for analysis.Where possible, we
tried to obtain the estimates of mean change from baseline values
for the outcomes (the baseline seemed to vary between groups for
most outcomes) using a digital graph reader (http://arohatgi.info/
WebPlotDigitizer/app/).
Primary outcomes
Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20
The study did not mention measuring quality of life.
Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS)
questionnaire and visual analogue scales)
The study didnot provide results for a patient-reported total symp-
toms score using an instrument validated in a chronic rhinosinusi-
tis population. Patients recorded the symptoms of blocked nose
(nasal obstruction) and runny nose (rhinorrhoea) for each nasal
cavity on a scale of 0 to 3 in a weekly diary and they were asked
whether they had experienced any change in smell using a 0 to 3
scale during clinic visits.
We estimated the point estimates for mean change from baseline
for individual symptom scores using the digital graph reader:
• Nasal congestion: the aqueous nasal spray and aerosol
groups improved by 0.6 and 0.4 points, respectively.
• Rhinorrhoea: we estimated the decrease in score from
baseline for the aerosol and aqueous nasal spray groups to be
about 0.5 points and 0.2 points, respectively.
• Change in sense of smell: the study reported there was no
“statistically significant difference” between the groups.
The significance of these differences is difficult to interpret, since
the magnitude is not large and the baseline scores were different.
Patients in the aerosol group consistently had less severe symptoms
at baseline compared to the spray group (by about 0.3 points).
Significant adverse effect: epistaxis
No details of adverse events were reported. The paper only stated
that “Few side effects such as dry nose, headache and epistaxis were
reported and with no difference between the treatment groups”.
Secondary outcomes
Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments
The study did not mention measuring quality of life.
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Other adverse effects: local irritation (including nasal
irritation, oral thrush, sore throat)
No details about adverse events were reported. The paper only
stated that “Few side effects such as dry nose, headache and epis-
taxis were reported and with no difference between the treatment
groups”.
Other adverse effects, such as stunted growth in children and
osteoporosis in adults (minimum time point: six months of
treatment and follow-up)
No details about adverse events were reported. The paper only
stated “Few side effects such as dry nose, headache and epis-
taxis were reported and with no difference between the treatment
groups”.
Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-
Kennedy/Lund-Mackay)
The study reported that “During the study a statistically significant
decrease mean total polyps scores was seen in both groups treated
with budesonide. The patients treated with placebo, however, had
amean increase in total polyps score during the treatment period.”
However, the “increase” in polyps size was only 0.1 points in the
placebo group, whereas the decrease in polyps size score was 0.6
in the aerosol group and 1.4 in the aqueous group. As with the
symptom score, the patients in the aerosol group had a lower
baseline severity score (by about 0.3 points).
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
There were no indications that CT scans were used.
The quality of the evidence is very low (GRADE) for all outcomes
in this comparison, due to very serious methodological concerns
and imprecision.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
High-dose versus low-dose intranasal corticosteroids for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is (all studies recruited pat ients with bilateral polyps)
Setting: studies most ly conducted in Europe/ North America about 10 years ago, in secondary care sett ings
Intervention: high-dose intranasal cort icosteroids
Comparison: low-dose intranasal cort icosteroids
Outcomes
of participants
(studies)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality What happens
Low-dose intranasal
corticosteroids
High-dose intranasal
corticosteroids
Difference
Disease-specif ic
health-related quality of
lif e
Not measured Impact unknown
Disease severity - overall symptoms, measured as average change f rom baseline at 4 months
All 4 EPOS domains No information available
3 domains (nasal block-
age, rhinorrhoea, loss
of sense of smell)
Range 0 to 3, lower
score = less severe
of part icipants: 237
(1 RCT)
- The mean disease
severity - overall symp-
toms, measured as
average change f rom
baseline at 4 months
(range 0 to 3) - aver-
age symptom score (3
domains) without high-
dose was
- 0.66 points
- MD 0.13 points lower
(0.37 lower to 0.11
more) than low-dose
group
⊕⊕©©
LOW 123
The average score for
3 types of symptoms
seems to be sim ilar
between the high-dose
and low-dose groups
(2 domains: nasal
blockage, rhinorrhoea)
Range 0 to 3, lower
score = less severe
- The mean disease
severity - overall symp-
toms, measured as
average change f rom
- MD 0.19 points lower
(0.36 lower to 0.02
lower) than low-dose
group
⊕⊕©©
LOW 123
The average score for
2 types of symptoms
seems to be slight ly
lower for the high-dose2
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of part icipants: 441
(2 RCTs)
baseline at 4 months
(range 0 to 3) - aver-
age symptom score (2
domains) without high-
dose was
- 0.73 points
group. The clinical sig-
nif icance of this reduc-
t ion is unclear
Disease severity - measured as average change f rom baseline at 4 months (range 0 to 3)
• Nasal blockage
(lower score = less
severe)
of part icipants: 441
(2 RCTs)
- The mean disease
severity - individual
symptoms, measured
as average change
f rom baseline at 4
months (range 0 to 3) -
nasal blockage without
high-dose was
- 0.86 points
- MD 0.24 points lower
(0.39 lower to 0.08
lower) than low-dose
group
⊕⊕©©
LOW 123
The nasal blockage
score seems to be
slight ly lower in the
high-dose group. The
clinical signif icance of
this reduct ion is unclear
• Rhinorrhoea
(lower score = less
severe)
of part icipants: 441
(2 RCTs)
- The mean disease
severity - individual
symptoms, measured
as average change
f rom baseline at 4
months (range 0 to 3)
- rhinorrhoea without
high-dose was
- 0.6 points
- MD 0.15 points lower
(0.33 lower to 0.03
higher) than low-dose
group
⊕⊕©©
LOW 123
The average score for
rhinorrhoea seems to
be sim ilar between the
high-dose and low-dose
groups
• Loss of sense of
smell (lower score =
less severe)
of part icipants: 237
(1 RCT)
- The mean disease
severity - individual
symptoms, measured
as average change
f rom baseline at 4
months (range 0 to 3) -
loss of sense of smell
without high-dose was
- MD 0.06 points higher
(0.2 lower to 0.32
higher) than low-dose
group
⊕⊕©©
LOW 123
The average score for
loss of sense of smell
seems to be very sim ilar
between the high-dose
and low-dose groups
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- 0.6 points
Adverse ef fects: epis-
taxis
of part icipants: 637
(4 RCTs)
RR 2.06
(1.20 to 3.54)
Study populat ion ⊕⊕⊕©
MODERATE 45
The risk of epistaxis is
likely to be higher in
the higher-dose groups.
However, the studies in-
cluded very minor nose-
bleeds, such as blood
stains in the mucus,and
most of these events
are not likely to be se-
vere
57 per 1000 118 per 1000
(69 to 202)
61 more per 1000
(11 more to 145 more)
Moderate
60 per 1000 124 per 1000
(72 to 214)
64 more per 1000
(12 more to 153 more)
Adverse ef fects: local
irritat ion
of part icipants: 542
(3 RCTs)
RR 0.97
(0.28 to 3.31)
Study populat ion ⊕⊕©©
LOW 467
The risk of local irrita-
t ion seems to be sim i-
lar between groups, but
the overall risks are un-
derest imated due to the
way the data were re-
ported
19 per 1000 18 per 1000
(5 to 62)
10 fewer per 1000
(13 fewer to 43 more)
Moderate
17 per 1000 17 per 1000
(5 to 58)
10 fewer per 1000
(13 fewer to 40 more)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; EPOS: European Posit ion Paper on Rhinosinusit is and Nasal Polyps 2012;M D: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SD:
standard deviat ion
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Scale validity, part icularly discrim inant validity (ability to dist inguish the dif ferences between groups), was unclear. There
was a high risk of report ing bias. Studies tended to report enough information for meta-analysis only for stat ist ically
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signif icant results. One study, which had 101 part icipants, reported very sim ilar values for both intervent ion arms for all
disease scores but had no information related to SD.
2Small sample size - evidence only f rom one or two relat ively small studies.
3Only data f rom patients with bilateral nasal polyposis. We considered this to be indirectness of the evidence to pat ients
without polyps but have not further downgraded the evidence.
4One of the studies had inadequate blinding - a double dummy was not used to mask the twice daily (higher) versus once
daily (lower) dose; the study had 101 part icipants.
5Sample size relat ively small f or a precise est imate of adverse events. We downgraded this outcome once, af ter taking into
considerat ion the inadequate blinding in one of the studies and the relat ively small sample size.
6Studies did not use consistent term inology/ methods to report dif f erent types of local irritat ion. For analysis we only selected
the most f requent types of local irritat ion f rom a list (to avoid double count ing). This is a possible underest imation of overall
event rates. The relat ively low event rates and small sample size contributed to the large conf idence intervals.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
We found nine studies reporting on four different comparisons
(Chur 2013; Demirel 2008; Filipovic 2006; Holmberg 1997;
Johansen 1993; Lund 1998; Penttila 2000; Small 2005; Stjarne
2006). Due to the choice of outcome measures used in these stud-
ies and the incomplete reporting of results, for most of the com-
parisons we were not able to find much evidence.
The following is a summary of the key findings for each compar-
ison:
Comparison 1: Different type of corticosteroids:
fluticasone propionate versus beclomethasone
dipropionate
We included two small studies in the review (Holmberg 1997,
n = 37; Lund 1998, n = 20). Both studies used 400 µg/day of
each drug, given twice a day using nasal sprays. They reported
very similar effectiveness between the groups in terms of disease
severity and epistaxis. However, these studies are too small to pro-
vide any certainty of the findings (GRADE assessment: very low
quality evidence). The other outcomes were either not measured
or very poorly reported. See Summary of findings for the main
comparison.
Comparison 2: Different types of corticosteroids:
fluticasone propionate versus mometasone furoate
We found only one study (Filipovic 2006, n = 100). This
study used a 200 µg daily dose administered as an aqueous
spray and found no difference in nasal symptom scores between
the groups.(GRADE assessment: very low quality evidence). See
Summary of findings for the main comparison.
Comparison 3: High-dose versus low-dose intranasal
steroids
We found five studies for this comparison. Three of these used
mometasone furoate (Chur 2013; Small 2005; Stjarne 2006): a
daily dose of 400 µg versus 200 µg for adults and older children,
200 µg versus 100 µg in younger children (Chur 2013). Demirel
2008 and Penttila 2000 used fluticasone propionate nasal drops
(a daily dose of 800 µg versus 400 µg).
Effectiveness (disease severity and nasal polyps size) was similar
between the high-dose and low-dose groups, except for a possibil-
ity of a small benefit in terms of nasal obstruction and rhinorrhoea
when using a higher dose of mometasone. Although all studies
reported more improvement in the polyps score in the high-dose
group, the significance of this is unclear due to the small size of the
improvements. However, the risk ratio (RR) for adverse events was
higher for epistaxis (RR 2.06, 95% confidence interval (CI) 1.20
to 3.54; 637 participants; four studies; I2 = 0%) (GRADE assess-
ment: moderate quality evidence). It is less clear whether the risk
of local irritation was similar due to the wide confidence intervals
and poorer reporting (RR 0.97, 95% CI 0.28 to 3.31; 542 par-
ticipants; four studies; I2 = 0%) (GRADE assessment: low quality
evidence). See Summary of findings 2.
Comparison 4: Different types of delivery methods:
aqueous nasal spray versus aerosol spray
We found only one study for this comparison (Johansen 1993).
This study was not well reported and there seemed to be baseline
differences in polyps size. The results for disease severity seemed
to be similar for symptom scores, but it is difficult to interpret the
importance of the difference of 0.5 points in polyps size due to
baseline differences.
In summary, despite having nine included studies there was not
much information available. All reports suggested similar effective-
ness between different types of intranasal corticosteroids, doses,
methods of administration and formulations. However, there is a
possibility of an increased risk of adverse effects, particularly epis-
taxis with the higher dose of mometasone furoate (400 µg versus
200 µg per day).
Overall completeness and applicability of
evidence
The doses used in the studies were in keeping with manufactur-
ers’ recommendations and are applicable to the population being
studied. The population of patients with chronic rhinosinusitis
with nasal polyps is likely to have intranasal steroids initiated as
a treatment in both primary and secondary care settings. There
were no studies that included patients with chronic rhinosinusitis
without nasal polyps for us to evaluate and this points to a defi-
ciency in the currently available evidence for this subgroup.
Disease-specific health-related quality of life, which is both specific
to the disease and important to patients, was not used in the
included studies as an outcome measure. There is therefore no
information at all on whether the different types of intranasal
steroids have an impact on patients’ quality of life.
Quality of the evidence
The quality of the evidence for all outcomes in these comparisons
was either low orvery low (GRADE assessment), due to the small
number of participants available for analysis (resulting in large
confidence intervals) and limitations in the methods of study con-
duct and reporting. There is a severe concern about selective re-
porting bias, particularly for the effectiveness data, where studies
only provided numerical data and P values (which allowed us to
estimate standard deviations) when there was a statistically signif-
icant difference between groups or against placebo.
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The only exception to our assessment of low/very low quality evi-
dence is the epistaxis outcome, where we can be more certain that
there is an increase in risk when higher doses of intranasal steroids
are used (GRADE assessment: moderate quality evidence).
Potential biases in the review process
In most cases the studies did not report enough information for us
to further analyse the results. We have had to take readings from
graphs using a digital graph reader and impute standard deviations
based on the P values reported. They were often only reported
as ’P value < 0.05’ or ’P value < 0.01’ in comparisons where the
studies found statistical significance. Our imputations are based
on these values (using P value = 0.01 or P value = 0.05) and we are
therefore conservative in our estimation of the standard deviations.
However, this lack of information about non-significant results
could have prevented us from drawing more conclusive results
about the lack of difference between groups.
For disease severity, we only aimed to include results measured
using validated instruments. However, none of the studies in this
review (and indeed most of the studies in our series of reviews
(Chong 2016a; Chong 2016b; Head 2016a; Head 2016b; Head
2016c) had used these. We therefore had to make a compromise
and we included results using non-validated scales in order to
obtain some information.
Agreements and disagreements with other
studies or reviews
This review is part of a series of reviews on chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Head 2016a; Head 2016b; Head
2016c). The purpose of this review is to answer the question
of whether there are any differences between the various types,
dosages and regimens of intranasal corticosteroids. A companion
review looks at the effectiveness of intranasal steroids compared to
placebo (Chong 2016a). We are not aware of other reviews that
have specifically looked at the relative effectiveness and safety of
different types of intranasal corticosteroids, doses and methods or
regimens of delivery. Although Chong 2016a planned subgroup
analyses for different types of steroids, doses and deliverymethods,
this was not carried out as heterogeneity was only observed for
one outcome (facial pain), where only two studies were included
and they differed in the population of patients (polyps versus no
polyps), types and doses of steroids used (128 µg/day budesonide
versus 800 µg/day fluticasone) andmethod of delivery (nasal drops
versus breadth actuated inhaler). That review found a higher risk
of epistaxis in patients on intranasal steroids versus placebo but
despite the inclusion of different doses, types of steroids and de-
livery methods, no heterogeneity was observed.
Recent international trials using the Optinose device (Navi-
gate trials I and II) have now been completed (NCT01622569;
NCT01624662). These studies have included differing doses
within their protocols, so further information on doses and devices
will be forthcoming once these results are published.
Two previous Cochrane reviews have looked at topical steroids in
people with chronic rhinosinusitis with nasal polyps (Kalish 2012)
and without nasal polyps (Snidvongs 2011), and also included
comparison of different types and doses of steroids in their scope.
Unlike these reviews, the present review only includes studies with
a minimum three-month duration of treatment and follow-up.
We excluded studies that investigated the impact of intranasal
steroids on surgical outcomes, either administered perioperatively
or within weeks of surgery to prevent relapses, from this review. Of
these, we excluded four studies included in Kalish 2012 because
the duration of treatment and follow-up did not meet the 12-week
inclusion criterion (range from four to eight weeks) (Filiaci 2000;
Jankowski 2001; Lildholdt 1995; Tos 1998), and one study that
only included patients after sinus surgery (Dijkstra 2004). These
reviews also did not find a difference between the doses or types
of intranasal steroids.
The EPOS 2012 document splits the chronic rhinosinusitis pop-
ulation into those with and without nasal polyps. In patients who
have chronic rhinosinusitis without nasal polyps they did not
find any direct evidence for intranasal corticosteroid intra-class
comparisons (e.g. comparing delivery methods, doses or different
steroids). For people with chronic rhinosinusitis with nasal polyps
the evidence for intranasal corticosteroid intra-class comparisons
was not explicitly stated as a comparison of interest, although sub-
group analyses were planned for topical delivery method (nasal
spray versus nasal drops) and corticosteroid type (modern ver-
sus first-generation). The comparison of high-dose versus low-
dose was not considered although the review stated that eight
studies reporting this comparison were identified (Dijkstra 2004;
Filiaci 2000; Jankowski 2001; Lildholdt 1995; Penttila 2000;
Small 2005; Stjarne 2006; Tos 1998). The ’intranasal corticos-
teroid versus placebo’ results were subgrouped according to de-
livery method and no differences were found, although it should
be acknowledged that this is indirect evidence. Similarly the com-
parison of ’modern’ versus ’first-generation’ intranasal steroids was
made by looking at an indirect subgroup analysis of intranasal
steroids versus placebo trials without mention of the three trials
that the authors identified specifically making this comparison
(Bross-Soriano 2004; Holmberg 1997; Lund 1998). The conclu-
sion of this analysis was that “Modern INCS do not have greater
clinical efficacy (although potentially fewer sider-effects [sic]) com-
pared to first-generation INCS”.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is clear that intranasal corticosteroids provide beneficial results
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in terms of symptom reduction and in the reduction of polyp
bulk within the nasal cavity (based on the evidence found in an
accompanying review; Chong 2016a). However, it is difficult to
suggest any advantages of one steroid molecule over the another
when administered as an intranasal corticosteroid. There is also
insufficient evidence to conclude whether there are any differences
between spray versus aerosol delivery.
The advantages of higher doses of intranasal corticosteroids appear
negligible and they are associatedwith an increased risk of epistaxis.
The studies included a broaddefinition of epistaxis and the severity
of episodes is unknown, but it is likely that the proportion of
events that required patients to discontinue use is low due to the
low numbers of withdrawals attributed to it. If epistaxis is limited
to streaks of blood in the mucus it may be tolerated by the patient
and it may be safe to continue treatment. However, it may be a
factor that affects compliance.
In conclusion, there is insufficient evidence to suggest that the
different types of corticosteroid molecule or spray versus aerosol
have different effects. Lower doses have similar effectiveness but
fewer side effects.
Implications for research
The results of this review, current to August 2015, conclude that
it is difficult to suggest any advantages of one steroid molecule
over the anotherwhen administered as an intranasal corticosteroid.
There is also insufficient evidence to conclude whether there are
any differences between the delivery methods. This review shows
that the largest number of included studies compared high-dose
and low-dose intranasal steroids and this aspect has therefore been
reasonably addressed to date. In addition, recent international tri-
als using the Optinose device (Navigate trials I and II), which
compare differing doses, have recently been completed, so further
information on doses should be available once these results are
published (NCT01622569; NCT01624662).
The advantages and disadvantages of differing steroid molecules
and the role of spray versus aerosol have not been investigated well
within the current trials and there is clearly room for further well-
conducted trials investigating this aspect of intranasal steroid use.
Future research should recruit patients with chronic rhinosinusi-
tis diagnosed using the EPOS 2012 criteria and include both pa-
tients with and without nasal polyps (stratified randomisation by
subgroup). Trials should focus on clinically relevant comparisons
and allow for comparisons of different types of intranasal steroids,
dosages or delivery methods.
The intervention and follow-up should be carried out for at least
three or six months, since intranasal corticosteroids are used as a
long-term treatment for a chronic condition. Ideally there should
be an aim to contact patients five years later, again due to chronicity
but also because there is evidence to suggest that symptom-based
outcomes plateau between six months and five years (Soler 2010).
It is recommended that any future research uses primary outcome
measures that are relevant to patients and any disease-specific in-
struments used should be validated in people with chronic rhinosi-
nusitis.Many studies, including the recentNavigate trials, chose to
use polyp scores as their primary outcome measure yet the correla-
tion between endoscopic results and patient symptoms is unclear.
The methods for defining and recording adverse events should
be considered at the protocol stage and adverse events recorded
should include epistaxis and local irritation; longer-term events
such as osteoporosis should also be considered.
This review is one of a suite of reviews of medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes.
• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
The development of a standardised set of outcomes, or core
outcome set, for chronic rhinosinusitis, agreed by researchers,
clinicians and patients, will facilitate this process.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chur 2013
Methods 4-arm, “double blind”, international, multicentre, parallel-group RCT, with a 4-month
duration of treatment and follow-up
Participants Location: 9 countries: Colombia, Guatemala, Honduras, Panama, Peru, Russia, South
Africa, Ukraine, United States. No. of sites not presented
Setting of recruitment and treatment: not stated
Sample size:
6 to 11 years
• Number randomised (6 to 11 years): 18 in intervention 1 (once daily), 18 in
intervention 2 (twice daily), 10 in comparison (placebo)
• Number completed (6 to 11 years): no information
12 to 17 years
• Number randomised (12 to 17 years): 32 in intervention 1, 33 in intervention
2, 16 in comparison
• Number completed (12 to 17 years): no information
Participant (baseline) characteristics:
6 to 11 years
• Age: twice daily group - 9.6, once daily group - 9.7, placebo group - 12.7
• Gender M/F: twice daily group - 5/13, once daily group - 8/10, placebo group -
12/14
• Main diagnosis: nasal polyps
• Polyps status: 100% with polyps
• Previous sinus surgery status: no information
Other important effect modifiers:
• Asthma: twice daily group - 1, once daily group - 3, placebo group - 6
• Eosinophilic: twice daily group - 3, once daily group - 5, placebo group - 9
12 to 17 years
• Age: twice daily group - 14.4, once daily group - 14.4, placebo group - 12.7
• Gender: twice daily group - 15/18, once daily group - 14/18, placebo group - 12/
14
• Main diagnosis: bilateral nasal polyps
• Polyps status: 100% with polyps
• Previous sinus surgery status: no information
Other important effect modifiers:
• Asthma: twice daily group - 4, once daily group - 9, placebo group - 6
• Eosinophilic: twice daily group - 3, once daily group - 9, placebo group - 9
Inclusion criteria: children aged 6 to 17 years with nasal polyposis
Exclusion criteria:
• Children younger than 6 years
• Antrochoanal polyps, cystic fibrosis, acute rhinosinusitis, rhinitis medicamentosa,
dyskinetic ciliary syndromes and aspirin allergy
• Patients with asthma who received inhaled corticosteroids were required to be on
no more than a moderate dosage regimen as defined by the 2005 Global Initiative for
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Chur 2013 (Continued)
Asthma Guidelines (GINA) for 1 month before screening and to remain on it
throughout the study (16); other forms of corticosteroids were prohibited
Interventions 6 to 11 years
Intervention 1 (n = 18): mometasone furoate nasal spray, 100 µg once per day for 4
months
Intervention 2 (n = 18): mometasone furoate nasal spray, 100 µg twice per day for 4
months
Comparator group (n = 10): placebo once or twice daily (combined), for 4 months
12 to 17 years
Intervention 1 (n = 26): mometasone furoate nasal spray, 200 µg once per day for 4
months
Intervention 2 (n = 32): mometasone furoate nasal spray, 200 µg twice per day for 4
months
Comparator group (n = 16): placebo once or twice daily (combined) for 4 months
Use of additional interventions (common to both treatment arms): inhaled corti-
costeroids for patients with asthma (up to the equivalent of a moderate dosage regimen
according to GINA 2005)
Outcomes Outcomes of interest in the review:
All outcomes were measured at 4 months
Primary outcomes:
1. Participants rated signs/symptoms including nasal congestion/obstruction, anterior
rhinorrhoea/postnasal drip and loss of sense of smell; rated daily by participants on a 4-
point scale
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation (including oral thrush, sore throat)
4. Polyps size, no details on scores used
Other outcomes reported by the study:
• (Primary outcome) Effects on hypothalamic-pituitary-adrenal (HPA) axis
function (24-hour urinary free cortisol change from baseline and 24-hour urinary free
cortisol corrected for creatinine/adverse events)
• Investigator-evaluated polyp size (on a 4-point scale)
• Investigator assessment of overall therapeutic response (on a 5-point scale ranging
from 0 (complete relief ) to 4 (no relief )
Funding sources “Editorial assistance was provided by Andrew Horgan, PhD, of AdelphiEden Health
Communications, New York, NY. This assistance was funded by Merck Sharpe and
Dohme Corp.”
Declarations of interest No information provided. (One of the authors of was affiliated with Merck Sharpe and
Dome; which was Schering-Plough in 2008 at the time of the study)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Chur 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were randomly assigned
to one of four treatment groups in a 4:4:1:
1 ratio... stratified by age”
Comment: pg 34, col 1, para 4
Allocation concealment (selection bias) Unclear risk Comment: no information about alloca-
tion concealment provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “received MFNS 200 mcg once
daily, MFNS 200 mcg twice daily, placebo
once daily, or placebo twice daily”
Comment: the abstract mentioned “dou-
ble-blind” and a placebo was used. How-
ever, instead of using a double-dummy de-
sign, where all participants received the
medication twice daily (with a placebo
given for those who had once daily treat-
ment), groups either had medication once
or twice daily. Therefore, there is no blind-
ing for participants in terms of knowing
whether they are on the once daily or twice
daily regimen
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: (as above)
Comment: most of the outcomes are pa-
tient-reported and therefore blinding of
outcome assessment is affected
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no information about loss to
follow-up or exclusion.However, only 119/
127 (93%) of randomised patients were
included in their primary endpoint analy-
sis. There were more exclusions/drop-outs
from the 100 µg group compared with the
higher-dose group (6 (12%) versus 1) but
no reasons were provided
Adverse effects and symptoms were re-
ported based on 127 participants. Unclear
whether there were any imputations
Selective reporting (reporting bias) High risk Quote: “No statistical analysis of effi-
cacy end points was pre-specified in the
study protocol, and only descriptive effi-
cacy statistics were collected.”
Comment: the protocol was identified
(NCT00378378) and the purpose as set
out in the protocol was “to evaluate the sa-
fety and efficacy of Nasonex® (Mometa-
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Chur 2013 (Continued)
sone Furoate Nasal Spray(MFNS)) in the
treatment of nasal polyps in pediatric sub-
jects between the ages of 6 and less than
18 years old. Safety will be the primary
focus of this study.” The study only re-
ported the change from baseline in points
and percentages but not the standard de-
viations and P values. The values from the
treatment groups were very similar to the
placebo group for some outcomes (e.g. -
43% for once daily versus -42% for placebo
for the outcome of rhinorrhoea). Poor re-
porting due to lack of beneficial effects can-
not be ruled out
Other bias Unclear risk Comment: there is no information regard-
ing the validation of the symptom score
Demirel 2008
Methods 3-arm, “double-blind”, parallel-group RCT, with a 12-week duration of treatment and
follow-up
Participants Location: Turkey, 1 site
Setting of recruitment and treatment: Department of Otorhinolaryngology, Faculty of
Medicine, Istanbul University
Sample size:
• Number randomised: 11 in once daily group, 15 in twice daily group
• Number completed: 10 in once daily group, 13 in twice daily group
Participant (baseline) characteristics:
• Mean age ± SD (range): twice daily group: 32.5 ± 7.8 (20 to 43), once daily
group: 49.8 ± 12.3 (30 to 63)
• Gender M/F: twice daily group: 5/8, once daily group: 6/4
• Main diagnosis: bilateral nasal polyposis
• Polyps status: 100% with polyps
• Previous sinus surgery status (polypectomy): twice daily group: 5 (38%), once
daily group: 6 (60%)
Other important effect modifiers:
• Aspirin sensitivity: twice daily group: 2 (15%), once daily group: 4 (40%)
Inclusion criteria: age 16 years or over with bilateral nasal polyposis
Exclusion criteria: presence of a purulent nasal discharge, allergic rhinitis, severe asthma,
cystic fibrosis, unstable or other serious concurrent disease, psychological disorders, as-
pirin intolerance,Churg-Strauss Syndrome,Kartagener’s syndrome orYoung’s syndrome;
the use of an oral or depot corticosteroid during the previous 3 months or astemizole
within 6 weeks before the study or other antihistamines within 48 hours before the last
presentation, required maintenance of parenteral or intranasal corticosteroids or cro-
molyn sodium (sodium cromoglycate), and the presence of any contraindication to cor-
ticosteroids. In addition, women of child-bearing age were included if they were not
42Different types of intranasal steroids for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Demirel 2008 (Continued)
pregnant or lactating, and were warned to take adequate contraceptive measures to avoid
becoming pregnant during the study
Interventions Intervention (n = 15): fluticasone proportionate nasal drops, 800µg/day (400 µg twice
daily) for 12 weeks
Control (n = 11): fluticasone proportionate nasal drops, 400 µg once daily for 12 weeks
Use of additional interventions (common to all treatment arms): some patients un-
derwent polypectomy at the end of trial
Outcomes Outcomes of interest in the review:
Secondary outcomes:
1) Polyps size, by rigid endoscope at 12 weeks. A 4-point scoring system was used (0 to
3) (definitions: 0 - no polyps, 1 - mild polyposis - small polyp not reaching to upper
edge of the inferior turbinate and causing only slight obstruction; 2 - moderate polyposis
- medium polyp reaching between the upper and lower inferior turbinate and causing
troublesome obstruction; 3 - severe polyposis - large polyp reaching below the lower edge
of the inferior turbinate and causing almost/total blockage)
Other outcomes reported by the study:
• Nasal volumes by acoustic rhinometry
• Physician-rated clinical symptom scores (nasal blockage score, rhinitis symptom
score, nasal discomfort score and smelling score); physician assessed weekly on a 4-
point scale (0 (none) to 3 (severe))
Funding sources No information provided
Declarations of interest No information provided
Notes One of the arms (fluticasone propionate nasal spray 200 µg per day given in 2 divided
doses) is not relevant to this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “…randomly divided…”
Comment: pg 3, col 1, para 3
No further information provided
Baseline age does not appear to be balanced:
themean age of the 400 µg twice daily nasal
group was about 17 years younger
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “…double-blind..”
Comment: pg 1, col 1, para 2 says that the
study was double-blinded but the interven-
tions were given in a different format (nasal
spray versus nasal drops) and at different
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Demirel 2008 (Continued)
frequencies (1 versus 2 times per day) so it
is difficult to see how either the personnel
or participants were blind to the interven-
tion). There was no mention of placebo
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no mention of placebo used;
difficult to see how investigators and/or
participants can be blinded to treatment in-
tervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 34 of 39 people randomised
completed the trial (87%) but those who
did not complete (of which 4/5 were due
to worsening of the condition) were not in-
cluded in the outcomes
Selective reporting (reporting bias) High risk Comment: numerical information was not
well provided; most information for symp-
toms was presented as figures
Other bias Unclear risk Comment: no information was provided
regarding the validation of the assessment
instruments used
Filipovic 2006
Methods Single-blinded, parallel-group RCT with 3 months treatment and follow-up
Participants Location: Serbia
Setting of recruitment and treatment: no information
Sample size:
• Number randomised: 62 in intervention, 38 in comparison
• Number completed: no information
Participant (baseline) characteristics:
• Age: range 24 to 65
• Gender: no information
• Main diagnosis: asthma patients with bilateral nasal polyposis
• Polyps status: 100% with polyps/no information
• Previous sinus surgery status: no information
• Previous courses of steroids: not reported
Other important effect modifiers, if applicable: all patients have asthma
Interventions Intervention (n = 62): fluticasone propionate aqueous nasal spray, 200 µg once daily,
for 3 months
Comparator group (n = 32): mometasone furoate aqueous nasal spray, 200 µg once
daily, for 3 months
Use of additional interventions (common to both treatment arms): not reported
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Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity symptom score, nasal symptoms score (postnasal drip, anterior rhin-
orrhoea, obstruction and loss of sense of smell), evaluated daily
Secondary outcomes:
Other outcomes reported by the study:
• No information on other outcomes
Funding sources “No information provided”
Declarations of interest “No information provided”
Notes Only an abstract was available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no information, only published
as an abstract. Unclear how randomisation
was generated. Ratio does not seem 1:1
Allocation concealment (selection bias) Unclear risk Comment: no information, only published
as an abstract
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “single blind…”
Comment: unclear who was blinded and
how blinding was maintained
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “single blind…”
Comment: unclear who was blinded and
how blinding was maintained
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no information on how many
randomised versus completed
Selective reporting (reporting bias) Unclear risk Comment: no information, only published
as an abstract
Other bias Unclear risk Comment: no mention of any validation
of outcome measures. No information to
assess whether baseline characteristics were
balanced
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Methods 3-arm, double-blind, parallel-group RCT, with a 26-week duration of treatment and 2
additional weeks of follow-up
Participants Location: Sweden, number of sites is unclear
Setting of recruitment and treatment: outpatient clinics
Sample size:
• Number randomised: 19 in FP group, 18 in BDP group, 18 in placebo group
• Number completed: 15 in FP group, 16 in BDP group, 11 in placebo group
Participant (baseline) characteristics:
• Age mean (range): group FP: 54 (27 to 74); BDP group: 49 (26 to 68); placebo
group: 47 (21 to 71)
• Gender (M/F): FP group: 15/4; BDP group: 13/5; placebo group: 14/4
• Main diagnosis: bilateral polyposis with a polyp score of 1 or 2
• Polyps status: 100% with polyps
• Previous sinus surgery status: 100% had history of at least 1 polypectomy within
the previous 5 years
Other important effect modifiers:
• Positive skin prick test (%): FP group: 3 (16%); BDP group: 6 (33%); placebo
group: 5/18 (27%)
Inclusion criteria: bilateral polyposis with a polyp score of 1 or 2
Exclusion criteria:nasal polyposiswith a score of 3 or 4 (or 0); concurrent nasal infection;
an inability to cease treatment with systemic, inhaled or intranasal steroids or sodium
cromoglycate on visit 1; had used antihistamines in the 48 hours prior to visit 1; had a
contraindication to steroids or had any serious or unstable concurrent disease
Interventions FP group (n = 19): fluticasone propionate, aqueous nasal spray, 2 actuations of 50 µg
each to each nostril morning and evening (400 µg/day) for 26 weeks
BDP group (n = 18): beclomethasone dipropionate, aqueous nasal spray, 2 actuations
of 50 µg each to each nostril morning and evening (400 µg/day) for 26 weeks
Placebo group (n = 18): placebo, actuations to each nostril morning and evening
containing the same vehicle, as the interventions solutions including benzalkonium
chloride as a preservative, for 26 weeks
Use of additional interventions (common to all treatment arms): a 4-week run-in
period during which no treatment for polyposis, except for rescue loratadine, could be
used by the patients
All patients were supplied with rescue loratadine tablets to use as relief medication, 10
mg loratadine once daily. Any use of rescue medication was documented on the patient’s
daily record card
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Patient-reported disease severity, measured by daily records of all their nasal symptoms
including: nasal blockage; sense of smell; sneezing and rhinorrhoea using a 4-point rating
system (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 4 = severe
symptoms)
2. Physician assessment of symptoms. No details were provided on how these were
measured. Measured at 26 weeks
3. Significant adverse effect: epistaxis
Secondary outcomes:
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4. Polyp size by endoscopy (0- to 4-point scale)
Other outcomes reported by the study:
5. Polyp score
6. Peak nasal inspiratory flow
7. Physician’s assessment of change in symptoms
Funding sources Glaxo Wellcome PLC, England and the Torsten and Ragnar Söderberg Foundation,
Sweden
Declarations of interest No conflicts of interest declared but 2 (of 6) authors had affiliationswithGlaxoWellcome
Plc
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”
Comment: pg 271, col 1, para 3
No further details provided
Allocation concealment (selection bias) Unclear risk Comment: no information provided in the
paper
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo: 2 actuations to each nos-
tril morning and evening containing the
same vehicle, as the fluticasone and be-
clomethasone solutions including benza-
lkonium chloride as a preservative. The
placebo solution was therefore identical to
the active treatments but did not contain
any active drug.”
Comment: pg 271, col 1, last para
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no further information. Should
also be low if there is adequate blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 13/54 patients (24%) did not
complete trial; 4/19 in fluticasone, 2/18
in beclomethasone, 7/18 (39%) in placebo
group. Uneven drop-out numbers: very
high in placebo group
Selective reporting (reporting bias) High risk Quote: “The primary efficacy endpointwas
the physician’s assessments of symptoms
and polyp score on all clinic visits”
Comment: the methods section described
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assessment of polyps, and patient-reported
symptom scores. However, “physician as-
sessment of outcomes and polyps score”
were reported as primary outcomes in
the results section. The results focused
on “physician assessment of symptoms”
and barely mention the results of the
polyps (only “significant” for visit 5 on
beclomethasone, not for fluticasone). In
addition, there were some outcomes that
seemed to have arbitrary, non-predefined
cut-off points (% of days with symptom
score < 2 in results). The denominator
for the reported symptom scores outcome
measures is not identified
Other bias High risk Comment: primary outcome of physician
assessment of outcomes was not well de-
scribed in the paper with little information
on the criteria used or any validation/inter-
rater reliability
Johansen 1993
Methods 3-arm, “double-blinded”, multicentre, parallel-group RCT, with a 3-month duration of
treatment and follow-up
Participants Location: 4 sites in Denmark, 1 site in Sweden
Setting of recruitment and treatment: unclear
Sample size:
• Number randomised: 91 (numbers allocated to each group unknown)
• Number completed: 86 (numbers allocated to each group unknown)
Participant (baseline) characteristics:
• Age median (range): 52 (18 to 78)
• Gender (M/F): 70/21
• Main diagnosis: eosinophilic nasal polyposis with polyp scores of 2 or less on each
side
• Polyps status: 100% with polyps
• Previous sinus surgery status: not provided in the paper
Other important effect modifiers:
• 22 patients had asthma (allocation between groups unknown)
• 8 patients were known to be acetylsalicylic acid (ASA) sensitive. (The ASA
sensitive patients did not change their polyp score during treatment.)
Inclusion criteria: clinical diagnosis of eosinophilic nasal polyposis with polyp scores
of 2 or less on each side. Eosinophilic polyposis was confirmed by nasal smear and/or
biopsy.
Exclusion criteria:
• Polyps surgically removed within 2 months
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• Neutrophilic polyposis
• Systemic or topical nasal corticosteroid therapy within 2 months
Interventions Group A (n = unknown): budesonide aqua (Rhinocort Aqua), 50 µg in each nostril x
2, twice daily (400 µg/day), 3 months
Group B (n = unknown): budesonide aerosol (Rhinocort Aerosol), 50µg in each nostril
x 2, twice daily (400 µg/day), 3 months
Group C (n = unknown): placebo (aqua or aerosol), unclear dose, 3 months
Use of additional interventions (common to all treatment arms): unclear - no infor-
mation was provided
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, measured weekly by patients. Symptoms included were nasal obstruc-
tion, sneezing and nasal secretions, recorded for each nasal cavity (scale 0 to 3).
Change in sense of smell was recorded at clinical visits using a scale of 0 to 3
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation (including oral thrush, sore throat)
4. Polyp size (assessed using a 0 to 3 scale - definitions provided)
Other outcomes reported by the study:
• Polyp size (assessed using a 0 to 3 scale - definitions provided)
• Nasal and oral peak inspiratory flow
• Nasal and oral peak expiratory flow
Funding sources Astra Danmark A/S and Astra Draco AB, Sweden supported the study financially
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomised…”
Comment: mentioned in abstract but no
further mention
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The patients were treated with ei-
ther budesonide aqua (Rhinocort Aqua)
or budesonide aerosol (Rhinocort Aerosol)
, 50 mcg x 2 in each nostril, twice daily =
400 mcg/day or placebo (aqua) or aerosol)
”
Comment: whilst there may be adequate
blinding for treatment versus placebo, there
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is no blinding when comparing different
dosage forms
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no further information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Five patients withdrew from the
study…”
Comment: no reasons given for with-
drawals. Not included in any of the out-
comes (including safety outcomes)
Selective reporting (reporting bias) Unclear risk Comment: all outcomes reported in the
methods are mentioned in the results sec-
tion, but numerical information for the re-
sults is not provided
Other bias High risk Comment: no comment on the validation
of outcome measurements
The paper does not provide clear back-
ground characteristics for each group. The
number randomised to each group was not
provided
Lund 1998
Methods Double-blind, parallel-group RCT, with a 12-week duration of treatment
Participants Location: UK
Setting of recruitment and treatment: tertiary referral centre (Royal National ENTHos-
pital London)
Sample size:
• Number randomised: 10 each in FP and BDP, 9 in placebo
• Number completed: unclear, likely to be all
Participant (baseline) characteristics:
• Age (mean, range): 52 (32 to 71), 46 (22 to 67) and 50 (27 to 69) in FP, BDP
and placebo arms
• Gender (M/F): 7/3, 9/1 and 7/2 in FP, BDP and placebo arms
• Main diagnosis: “severe polyposis”
• Polyps status: all had polyps, median total polyps score of 4 (both nostrils) using
Lund-Mackay CT score
• Previous sinus surgery status: 66% had surgery (7/10 in FP and BDP arms, 5/9 in
placebo)
• 59% had condition for more than 10 years
• All had allergy
Inclusion criteria:
Older than 16 years with a diagnosis of bilateral nasal polyposis requiring surgical inter-
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ventions, meeting one or more of the following criteria:
• a total polyp score of 4 or higher plus a CT scan score > 12;
• a total polyp score of 3 or higher, a nasal blockage score of 2 or higher, plus a CT
scan score > 12; and
• a total polyp score of 2 or higher, a nasal blockage score of 2 or higher, a CT scan
> 12, plus an UPSIT score > 32.
Exclusion criteria:
• Concurrent purulent nasal infection
• A requirement for more than 1000 µg beclomethasone (or equivalent) per day for
the treatment of asthma
• An inability to cease treatment with parenteral and intranasal corticosteroids or
cromolyn sodium (sodium cromoglycate) at visit 1, used astemizole in the 6 weeks
before the study or other antihistamines in the 48 hours before visit 1, or a
contraindication to corticosteroid medications
Interventions Intervention 1 (n = 10): fluticasone propionate aqueous nasal spray 400 µg per day, 2
actuations into each nostril morning and night
Intervention 2 (n = 10): beclomethasone dipropionate aqueous nasal spray 400 µg per
day, 2 actuations into each nostril morning and night
Comparator (n = 9): placebo 2 sprays into each nostril twice a day
Use of additional interventions (common to both treatment arms): terfenadine 60
mg as rescue medicine
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Disease severity - collected patient diaries on a 0 to 4 scale for different symptoms,
but only partially reported symptom-free days
Secondary outcomes:
• Adverse events - local irritation
• Endoscopy - polyps size (scale not reported)
Other outcomes reported by the study:
• PNIF, physician-reported score for symptom severity
Funding sources No information provided
Declarations of interest No information provided, but 2 of the authors were employed by Glaxo Wellcome and
reprint requests were addressed to Glaxo
Notes Study had a 4-week run-in period
34patientsmet criteria, 5withdrewbefore randomisation (1AE, 1 required polypectomy,
1 lack of efficacy, 2 did not return)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly allocated,
using a computer-generated random code
and a block size of 6, to receive 1 of 3 treat-
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ments”
Comment: adequate sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly allocated,
using a computer-generated random code
and a block size of 6, to receive 1 of 3 treat-
ments”
Comment: method not specified; blocked
randomisation, but adequate blinding.Un-
clear if allocation concealment remained
well maintained for this very small study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The placebo was identical to the
active formulations with the active ingredi-
ent omitted andwas indistinguishable from
the active treatments, which were them-
selves identical in appearance, taste, and
smell.”
Comment: there was a 4-week pre-treat-
ment period where all patients were ex-
posed to the placebo, but blinding should
still be adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: the same investigator did all the
clinical assessments for all visits, but an
identical placebo was used
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “last value carried forward tech-
nique” was used
Comment: drop-outs not balanced, 3/10
in fluticasone propionate, 0/10 in be-
clomethasone and 4/9 in placebo
Selective reporting (reporting bias) High risk Comment: patient-reported symptoms
were collected (using diaries), but it was
not specified how these were planned to
be reported. Study only reported percent-
age of patients with 100% of days without
nasal blockage, and the median % of days
without nasal symptoms (different criteria)
. Other outcomes not reported at all
There was also a higher percentage of pa-
tients in the fluticasone group (70%) com-
pared to 33% and 30% in the beclometha-
sone and placebo groups, but details were
not reported. Only stated that one of the
adverse events in the FP group (throat irri-
tation) was “predictable”
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Other bias High risk Quote: “overall rhinitis symptoms (sneez-
ing, rhinorrhoea, nasal itching)”
Comment: symptoms scores (by patients
and clinicians) were used but no mention
of validation. Some items seems to be sin-
gle symptom (e.g. nasal blockage), but oth-
ers seems to encompass a few things (e.g.
“overall rhinitis symptoms”)
Quote: “There was evidence, particularly
from the acoustic rhinometric and PNIF
data, that the patients randomly allocated
to receive BDANS had milder symptoms
than those randomly allocated to receive
FPANSor placebo, even though all patients
had been listed for surgical treatment on an
equal basis before the study.”
Comment: baseline symptoms and other
assessment scores were not reported. Un-
able to judge for other aspects
Penttila 2000
Methods 3-arm, double-blind, international, multicentre, parallel-group RCT, with a 12-week
duration of treatment
Participants Location: 12 centres in Denmark (3 centres), Finland (1 centre) and Sweden (1 centre)
Setting of recruitment and treatment: no information provided
Sample size:
• Number randomised: 47 in 400 µg FPND twice daily, 48 in 400 µg FPND once
daily, 47 in placebo
• Number completed: 45 in 400 µg FPND twice daily, 47 in 400 µg FPND once
daily, 41 in placebo
Participant (baseline) characteristics:
• Age: mean 51 (range 22 to 83)
• Gender: M/F; 107/35 (%M; 75.4%)
• Main diagnosis: nasal polyposis
• Polyps status: 100% with polyps
• Previous sinus surgery status: 72% previous polypectomy (not within 3 months of
trial)
Inclusion criteria: at least 16 years old, bilateral mild or moderate nasal polyposis
Exclusion criteria: severe polyposis (large polyps reaching below the lower edge of the
inferior turbinate, causing total obstruction), concurrent purulent nasal infection, unable
to cease treatment with intranasal steroids or sodium cromoglycate during run-in period.
Also excluded: people currently receiving inhaled corticosteroids or who had received
depot or oral steroids within previous 3 months, patients who had received astemizole in
6 weeks prior to first clinic visit, patients who had undergone nasal polyp surgery in the
previous 3months, patients with hypersensitivity or contraindication to steroids, patients
with allergic rhinitis or any other disease likely to interfere with outcomes, patients who
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were pregnant, lactating or likely to become pregnant during the study period
Interventions Intervention A (n = 47): fluticasone propionate nasal drops (FPND), 400 µg twice daily
for 12 weeks
Intervention B (n = 48): fluticasone propionate nasal drops (FPND), 400 µg once daily
for 12 weeks plus placebo drops once daily for 12 weeks
Comparator group C (n = 47): placebo nasal drops twice daily for 12 weeks
Process: contents were divided between both nostrils (200 µg per nostril) in the head
down and forward position
Use of additional interventions (common to both treatment arms): all patients un-
derwent a 2-week run-in period during which they ceased all medication for polyposis
except loratadine tables for relief of troublesome symptoms (10 mg daily maximum)
Initial visit: physical and oropharyngeal examinations and details of clinical history
Initial and 12-week visit: blood and urine samples
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, measured by assessing nasal blockage (0 to 3 scale) and overall rhinitis
symptoms including sneezing, rhinorrhoea and nasal itching (0 to 3 scale) and sense of
smell (0 to 3 scale) at 12 weeks after treatment
2. Significant adverse effect: epistaxis
Secondary outcomes:
3. Other adverse effects: local irritation
Other outcomes reported by the study:
Polyp size, degree of nasal blockage, overall rhinitis, peak nasal inspiratory flow (PNIF),
olfactory function, rescue medication usage and adverse events
Funding sources Funded by Glaxo Wellcome plc, UK
Declarations of interest No information provided - but one of the authors worked at Glaxo Wellcome Research
and Development
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…double blind randomised treat-
ment...”, Figure 1, pg 95
Comment: no further information pro-
vided, but this is an “international, multi-
centre” study in 12 centres across 3 coun-
tries with regional monitors. Should have
adequate sequence generation procedures
Allocation concealment (selection bias) Low risk Quote: “…double blind randomised treat-
ment...”, Figure 1, pg 95
Comment: no further information pro-
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vided. As above, allocation concealment
should be adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “active and placebo nasal drops
were provided in identical single-dose con-
tainers …”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no further information pro-
vided. Should be adequate with use of ad-
equate double-blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Sixteen patients were withdrawn
during the randomized treatment phase,
the majority due to lack of efficacy (five
placebo, one FP 400 mg o.d., two FP 800
mg b.i.d.) or adverse events (five placebo,
one FP 400mg o.d., two FP 400mg b.i.d.).
One patient in the placebo group withdrew
due to requirement for polypectomy. Two
patients withdrew during the open phase,
one requiring a polypectomy, the other for
unspecified reasons”, pg 97, column 2
Comment: 16/142 (11.3%) withdrew; 10/
47 placebo, 4/47 400 µg twice daily and 2/
48 400 µg once daily did not complete the
study. All these patients were included as
the ITT population. Percentage in placebo
group higher, but still quite small
Selective reporting (reporting bias) Unclear risk Comment: all outcome measures in the
methods section were discussed in the re-
sults section
Other bias Unclear risk Comment: no mention of validation of the
symptom criteria used for the primary out-
comes
Small 2005
Methods 3-arm, double-blind, multicentre, parallel-groupRCT, with a 4-month duration of treat-
ment and follow-up
Participants Location: 44 medical centres “worldwide”
Setting: no information
Sample size:
• Number randomised: 122 in 400 µg, 115 in 200 µg, 117 in placebo group,
respectively
• Number completed: 109 in 400 µg, 101 in 200 µg, 95 in placebo group,
respectively
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Participant (baseline) characteristics:
• Main diagnosis: bilateral nasal polyps and clinically significant congestion/
obstruction
• Age (mean): 400 µg: 48.3; 200 µg: 46.7; placebo: 47.5
• Gender (%M/%F): 400 µg: 61/39; 200 µg: 66/34; placebo: 61/39
• Polyps status: 100% with polyps
• Previous sinus surgery status: no information
Other important effect modifiers:
• Asthma history (%): 400 µg: 21; 200 µg: 18; placebo: 21
• Perennial allergic rhinitis history (%): 400 µg: 25; 200 µg: 20; placebo: 17
Inclusion criteria:
• ≥ 18 years with an endoscopically confirmed diagnosis of bilateral nasal polyps
(at least 1 on a scale of 0 to 3) and clinically significant nasal congestion/obstruction
(average morning score of 2 or higher on a scale of 0 to 3 for each of the last 7 days of
the 14-day run-in period)
• If had asthma, had a documented FEV1 ≥ 80% of the predicted value within the 6
months before screening and no asthma exacerbations within 30 days before screening.
Those treated with inhaled corticosteroids were required to be on a moderate, stable
regimen of beclomethasone dipropionate ≤ 800 mg/d or equivalent for 1 month
before screening and to remain on a stable regimen throughout the study period.
Exclusion criteria:
• Seasonal allergic rhinitis within the past 2 years
• Sinus or nasal surgery within the previous 6 months or 3 nasal surgeries (or any
surgical procedure preventing an accurate grading of polyps)
• Presumed fibrotic nasal polyposis, or complete or near complete nasal obstruction
• Nasal septal deviation requiring corrective surgery
• Nasal septal perforation
• Acute sinusitis, nasal infection or upper respiratory tract infection at screening or
in the 2 weeks before screening
• Ongoing rhinitis medicamentosa
• Churg-Strauss syndrome
• Dyskinetic ciliary syndromes
• Cystic fibrosis
• Glaucoma or a history of posterior subcapsular cataracts; allergies to
corticosteroids or aspirin, or any other clinically significant disease that would interfere
with the evaluation of therapy
Interventions 400 µg group (n = 122):mometasone furoate nasal spray 200 µg twice daily (morning
and evening) for 4 months
200 µg group (n = 115):mometasone furoate nasal spray 200 µg once daily (morning,
matching placebo used in the evening) for 4 months
Placebo group (n = 117): placebo nasal spray twice daily (morning and evening) for 4
months
Use of additional interventions (common to both treatment arms): acetaminophen
(paracetamol) was encouraged for analgesic purposes; NSAIDs limited to 5 consecutive
days if alternative analgesia was required. Antibiotics were administered for bacterial
infections at the discretion of the principal investigator
Concomitant medications that would interfere with study evaluations were not permit-
ted, including nasal sodium cromolyn; nasal atropine or ipratropium bromide; corticos-
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teroids (except oral inhaled corticosteroids for asthma or mild-strength or mid-strength
topical corticosteroids for dermatologic purposes); antihistamines; decongestants; topi-
cal, oral or ocular anti-inflammatory drugs; or topical nasal or oral antifungal agents
Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, patient evaluation of symptoms (congestion/obstruction, loss of sense
of smell, anterior rhinorrhoea and postnasal drip) measured daily on a diary card on a
4-point scale (0 = none, 3 = severe)
2. Significant adverse effect: epistaxis (defined to include a wide range of bleeding
episodes, from frank bleeding to bloody nasal discharge to flecks of blood in the mucus)
Secondary outcomes:
3. Other adverse effects: local irritation
Other outcomes reported by the study:
• Polyps grade; bilateral score and proportion of patients demonstrating an
improvement at endpoint
• Therapeutic response (rated by investigator)
• Peak nasal inspiratory flow
• Treatment compliance
• Number of withdrawals due to AE and events occurring in more than 2% of
participants in any group
Funding sources Supported by a grant from the Schering-Plough Research Institute
Declarations of interest The lead author received research support for POP1998 SAR study, PO1025 Polyps
study, PPO2573 Follow up to Polyps study PO2683 Acute rhinosinusitis and PO2692
Acute rhinosinusitis study. The source of the grant was not stated
2 of the authors were employed by Schering Plough; another author received a research
grant from Schering Plough and other pharmaceutical companies
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “…randomised in a 1:1:1 ratio to
3 treatment arms…”
Comment: pg 1276, col 1, para 2. No fur-
ther information. However, this is a rel-
atively recent “international, multicentre”
study in 44 centres worldwide. It should
therefore have adequate sequence genera-
tion procedures
Allocation concealment (selection bias) Low risk Comment: no information. However, this
is a relatively recent “international, multi-
centre” study in 44 centres worldwide. It
should therefore have adequate sequence
57Different types of intranasal steroids for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Small 2005 (Continued)
generation procedures
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind, double dummy”;
“… matching placebo nasal spray …”
Comment: pg 1276, col 1, para 1 and 2.
“Matching placebo spray” mentioned and
those on the 200 µg/day regimen were also
given placebo nasal spray for the evening
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no information. Likely to re-
main well blinded until end of study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: 305/354 patients (86%) patients
“completed 4-month treatment period”
Comment: higher % of patients not com-
pleting in the placebo group 22/117 (19%)
; compared to the twice daily or once daily
groups 13/122 (11%) and 14/114 (12%)
, respectively. Study mentioned analyses
based on “all randomised subjects” using
the “ITT principle” and endpoint was “de-
fined as the last non-missing reading for the
subject” for bilateral polyps score; however,
it is unlikely all were analysed as the num-
bers do not tally exactly with the “meta-
analysis subsequently reported”
Selective reporting (reporting bias) Low risk Comment: all outcomes reported in the
methods section were reported in the re-
sults section
Other bias Unclear risk Comment: no information about the vali-
dation of outcome measures
Stjarne 2006
Methods 3-arm, double-blind, multicentre, parallel-groupRCT, with a 4-month duration of treat-
ment and follow-up
Participants Location: 24 centres in 17 countries worldwide
Setting: study conducted from 25 June 2001 to 20 January 2003
Sample size:
• Number randomised: 102 in 400 µg, 102 in 200 µg, 106 in placebo group,
respectively
• Number completed: 93 in 400 µg, 94 in 200 µg, 87 in placebo group,
respectively
Participant (baseline) characteristics:
• Main diagnosis: bilateral nasal polyps and clinically significant congestion/
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obstruction
• Age (mean): 400 µg: 47.6; 200 µg: 47.2; placebo: 50.9
• Gender (%M/%F): 400 µg: 62/38; 200 µg: 70/30; placebo: 65/35
• Polyps status: 100% with polyps
• Previous sinus surgery status: not more than 3 times or within past 6 months
Other important effect modifiers:
• Asthma history (%): 400 µg: 19; 200 µg: 15; placebo: 17
• Perennial allergic rhinitis history (%): 400 µg: 18; 200 µg: 14; placebo: 22
Inclusion criteria:
• ≥ 18 years with an endoscopically confirmed diagnosis of bilateral nasal polyps
and clinically significant nasal congestion/obstruction (average morning score of 2 or
higher on a scale of 0 to 3 for each of the last 7 days of the 14-day run-in period)
• If had asthma, had a documented FEV1 ≥ 80% of the predicted value within the
6 months before screening and no asthma exacerbations within the 30 days before
screening. Those treated with inhaled corticosteroids were required to be on a
moderate, stable regimen of beclomethasone dipropionate ≤ 800 mg/d or equivalent
for 1 month before screening and to remain on a stable regimen throughout the study
period.
Exclusion criteria:
• Seasonal allergic rhinitis within the past 2 years
• Sinus or nasal surgery within the previous 6 months or 3 nasal surgeries (or any
surgical procedure preventing an accurate grading of polyps)
• Presumed fibrotic nasal polyposis, or complete or near complete nasal obstruction
• Nasal septal deviation requiring corrective surgery or nasal septal perforation
• Acute sinusitis, nasal infection or upper respiratory tract infection at screening or
in the 2 weeks before screening
• Ongoing rhinitis medicamentosa
• Churg-Strauss syndrome
• Dyskinetic ciliary syndromes
• Cystic fibrosis
• Glaucoma or a history of posterior subcapsular cataracts
• Allergies to corticosteroids or aspirin, or any other clinically significant disease
that would interfere with the evaluation of therapy
Interventions 400 µg group (n = 102):mometasone furoate nasal spray 200 µg twice daily (morning
and evening) for 4 months
200 µg group (n = 102):mometasone furoate nasal spray 200 µg once daily (morning,
matching placebo used in the evening) for 4 months
Placebo group (n = 106): placebo nasal spray twice daily (morning and evening) for 4
months
Use of additional interventions (common to both treatment arms): acetaminophen
(paracetamol) was encouraged for analgesic purposes; NSAIDs limited to 5 consecutive
days if alternative analgesia was required. Antibiotics were administered for bacterial
infections at the discretion of the principal investigator
Concomitant medications that would interfere with study evaluations were not permit-
ted, including nasal sodium cromolyn; nasal atropine or ipratropium bromide; corticos-
teroids (except oral inhaled corticosteroids for asthma or mild-strength or mid-strength
topical corticosteroids for dermatologic purposes); antihistamines; decongestants; topi-
cal, oral, or ocular anti-inflammatory drugs; or topical nasal or oral antifungal agents
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Outcomes Outcomes of interest in the review:
Primary outcomes:
1. Disease severity, patient evaluation of symptoms (congestion/obstruction, loss of sense
of smell, anterior rhinorrhoea and postnasal drip) measured daily on a diary card on a
4-point scale (0 = none, 3 = severe)
2. Significant adverse effect: epistaxis (defined to include a wide range of bleeding
episodes, from frank bleeding to bloody nasal discharge to flecks of blood in the mucus)
Secondary outcomes:
3. Other adverse effects: local irritation
Other outcomes reported by the study:
• Polyps grade; bilateral score and proportion of patients demonstrating an
improvement at endpoint
• Therapeutic response (rated by investigator)
• Peak nasal inspiratory flow
• Treatment compliance
• Number of withdrawals due to AE and events occurring in more than 2% of
participants in any group
Funding sources Supported by a grant from the Schering-Plough Research Institute
Declarations of interest “Schering Plough (manufacturer) was involved in the design and data analysis of this
study and reviewed and approved this article”
Dr Stjarne received payment of “approximately $50000 annually” from themanufacturer
for a contribution to the Clarityn website. Dr Mosges was on the advisory board and
Drs Staudinger and Danzig were employees of Schering-Plough
Notes The study had a 14-day, single-blind run-in period to exclude placebo responders and
identify participants with stable disease
The number of people screened/excluded after the run-in period is not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed in
blocks of 3 using random numbers gener-
ated by SAS functionUNIFORM(SAS In-
stitute, Cary, NC) with seed based on clock
time. Randomization was stratified by the
presence or absence of concurrent asthma.
”
Comment: computerised randomisation
Allocation concealment (selection bias) Low risk Comment: although randomisation was
blocked, blinding should be adequate
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”; “…matching
placebo nasal spray …”
Comment: “Matchingplacebo spray”men-
tioned; dosing regimen the same across all
groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no information. Likely to re-
mainwell blinded until the end of the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “More than 85% of subjects com-
pleted the 4-month treatment period, with
more than twice as many placebo recipients
as active drug recipients discontinuing dur-
ing the treatment phase (18% vs 8%).”
Comment: drop-out rates not balanced
Selective reporting (reporting bias) Unclear risk Comment: although all outcomes men-
tioned in the methods were reported, these
were mostly not in sufficient detail (e.g.
only P values)
Other bias Unclear risk Comment: no information about the vali-
dation of outcome measures
AE: adverse event
ASA: acetylsalicylic acid
BDP: beclomethasone dipropionate
CT: computerised tomography
d: day
F: female
FEV1: forced expiratory volume in one second
FP: fluticasone propionate
FPND: fluticasone propionate nasal drops
ITT: intention-to-treat
M: male
NSAIDs: non-steroidal anti-inflammatory drugs
PNIF: peak nasal inspiratory flow
RCT: randomised controlled trial
SD: standard deviation
UPSIT: University of Pennsylvania Smell Identification Test
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bross-Soriano 2004 POPULATION: all patients underwent endoscopic polypectomy at the start of the trial
Cannady 2005 STUDY DESIGN: not randomised
Dijkstra 2004 POPULATION: treatment started 1 week after FESS (continued for 1 year)
Filiaci 2000 DURATION: treatment and follow-up only 8 weeks
Fowler 2002 DURATION: treatment and follow-up only 8weeks (study compared betamethasone nasal drops (dose unclear)
versus 400 µg fluticasone propionate drops)
Giger 2003 POPULATION: allergic and non-allergic rhinitis patients
Jankowski 2001 DURATION: treatment only 8 weeks
Keith 1995 DURATION: treatment only 1 month (budesonide: 800 µg versus 400 µg versus placebo)
Lildholdt 1995 DURATION: treatment and follow-up only 4 weeks (budesonide: 400 µg versus 200 µg versus placebo)
NCT00788463 OTHER: trial registry entry for a clinical trial of “Beclomethasone aqueous spray and aerosol delivery systems
in nasal polyps”, registered in 2008. Contact with the study authors identified that this study was not completed
and no results were published. The reason for termination was not provided
NCT01405339 DURATION: treatment only 30 days. (Study compared 2 delivery methods for budesonide (mucosal atomi-
sation device versus saline rinse bottle) in patients with CRSwNP)
NCT01623310 STUDY DESIGN: not a randomised study
Ongoing study evaluating the safety of intranasal administration of 400 µg of fluticasone propionate twice a
day using a novel bi-directional device in participants with chronic rhinosinusitis with or without nasal polyps
NCT02194062 POPULATION: this study looked at the impact of fluticasone spray versus budesonide respules on patients
who just had FESS
Raghavan 2006 INTERVENTION: comparison of different head positions; treatment only 6 weeks
Reychler 2015 INTERVENTION: compared different doses (512 µg per day versus 2000 µg per day) and delivery methods
of budesonide (nasal spray versus nebulisation). Also had an oral steroids group
DURATION: treatment and follow-up only 16 days
Singhal 2008 POPULATION: all patients had sinus surgery
Toft 1982 INTERVENTION: beclomethasone dipropionate 400 µg per day delivered as a nasal spray or through a
“home-made insufflator, consisting of a nose-olive, a plastic tube and a funnel” to inhale powder fromRotacaps
capsules meant for asthma treatment
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Tos 1998 DURATION: treatment and follow-up only 6 weeks
Wang 2012 DURATION: treatment only 1 week
CRSwNP: chronic rhinosinusitis with nasal polyps
FESS: functional endoscopic sinus surgery
Characteristics of studies awaiting assessment [ordered by study ID]
Bachert 2004
Methods -
Participants -
Interventions -
Outcomes -
Notes Conference proceeding: we cannot locate the abstract
Meln 2004
Methods -
Participants -
Interventions -
Outcomes -
Notes Conference proceeding: we cannot locate the abstract
Pisano 2000
Methods -
Participants -
Interventions -
Outcomes -
Notes Conference proceeding: we cannot locate the abstract
63Different types of intranasal steroids for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reim 2005
Methods -
Participants -
Interventions -
Outcomes -
Notes We cannot locate the abstract
Characteristics of ongoing studies [ordered by study ID]
NCT01622569
Trial name or title ’Study evaluating the efficacy and safety of intranasal administration of 100, 200, and 400 µg of fluticasone
propionate twice a day (bid) using a novel bi directional device in subjects with bilateral nasal polyposis
followed by an 8-week open-label extension phase to assess safety’
Methods Double-blind, parallel assignment, randomised controlled trial
Participants Adults with bilateral nasal polyposis
Interventions • Fluticasone propionate 100 µg twice a day
• Fluticasone propionate 200 µg twice a day
• Fluticasone propionate 400 µg twice a day
• Matching placebo
For 16 weeks
Outcomes • Reduction of nasal congestion/obstruction symptoms
• Reduction in total polyp grade (sum of scores from both nasal cavities)
No secondary outcomes were listed in the trial registry entry
Starting date 2013
Contact information Optinose US Inc. No further details provided.
Notes Study has been listed as completed on the registry website (October 2015). No results are currently available
NCT01624662
Trial name or title ’Efficacy and safety study of intranasal administration of 100, 200, and 400 µg of fluticasone propionate
twice a day (bid) using a novel bi directional device in subjects with bilateral nasal polyposis followed by an
8-week open-label extension phase to assess safety’
Methods Double-blind, parallel assignment, randomised controlled trial
Participants Adults with bilateral nasal polyposis
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Interventions • Fluticasone propionate 100 µg twice a day
• Fluticasone propionate 200 µg twice a day
• Fluticasone propionate 400 µg twice a day
• Matching placebo
For 16 weeks
Outcomes • Reduction of nasal congestion/obstruction symptoms
• Reduction in total polyp grade (sum of scores from both nasal cavities)
No secondary outcomes were listed in the trial registry entry
Starting date 2012
Contact information Optinose US Inc. No further details provided.
Notes Study has been listed as completed on the registry website (October 2015). No results are currently available
NCT01946711
Trial name or title ’Buparid/PARI SINUS versus Budes® nasal spray in the therapy of chronic rhinosinusitis with polyposis nasi’
Methods Open-label, parallel assignment randomised controlled trial
Participants Chronic rhinosinusitis with polyposis nasi in adult patients
Interventions Budesonide inhalation versus budesonide spray
Outcomes Change of inflammation of the nasal mucosa and paranasal sinus
Magnetic resonance imaging (thickness of mucosa, Lund-Mackay score)
Safety assessment,
SNOT-22 quality of life
Nasal obstruction
Endoscopic evaluation of nasal polyps
Starting date 2013
Contact information Stefanie Prante (stefanie.prante@pari.com)
Notes Also registered as EUCTR 2013-002414-12 on European Registry
Study authors were contacted and responded to say that the trial is due to be completed in 2016
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D A T A A N D A N A L Y S E S
Comparison 1. High-dose versus low-dose intranasal corticosteroids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Disease severity - overall
symptoms, measured as average
change from baseline at 4
months (range 0 to 3)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Average symptom score (3
domains)
1 237 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.39, 0.12]
1.2 Average symptom score (2
domains)
2 441 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.40, -0.03]
2 Disease severity - individual
symptoms, measured as average
change from baseline at 4
months (range 0 to 3)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Nasal blockage 2 441 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.47, -0.10]
2.2 Rhinorrhoea 2 441 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.34, 0.03]
2.3 Loss of sense of smell 1 237 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.20, 0.31]
3 Adverse effects: epistaxis 4 637 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [1.20, 3.54]
4 Adverse effects: local irritation 3 542 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.28, 3.31]
5 Nasal polyps size, measured as
change from baseline (0 to 3
range scale) at 4 months
1 237 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.16, 0.54]
6 Nasal polyps - proportion with
improvement at 12 weeks
1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.91, 3.21]
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Analysis 1.1. Comparison 1 High-dose versus low-dose intranasal corticosteroids, Outcome 1 Disease
severity - overall symptoms, measured as average change from baseline at 4 months (range 0 to 3).
Review: Different types of intranasal steroids for chronic rhinosinusitis
Comparison: 1 High-dose versus low-dose intranasal corticosteroids
Outcome: 1 Disease severity - overall symptoms, measured as average change from baseline at 4 months (range 0 to 3)
Study or subgroup High-dose Low-dose
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Average symptom score (3 domains)
Small 2005 (1) 122 -0.79 (0.98) 115 -0.66 (0.91) 100.0 % -0.14 [ -0.39, 0.12 ]
Subtotal (95% CI) 122 115 100.0 % -0.14 [ -0.39, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Average symptom score (2 domains)
Small 2005 (2) 122 -0.92 (0.94) 115 -0.7 (0.87) 53.6 % -0.24 [ -0.50, 0.01 ]
Stjarne 2006 (3) 102 -0.92 (0.89) 102 -0.76 (0.89) 46.4 % -0.18 [ -0.45, 0.10 ]
Subtotal (95% CI) 224 217 100.0 % -0.21 [ -0.40, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
-2 -1 0 1 2
Favours high-dose Favours low-dose
different).
(1) Average of loss of sense of smell, anterior rhinorrhoea and obstruction scores. SD estimated from reported P values.
(2) Average of anterior rhinorrhoea and obstruction scores. SD estimated from reported P values.
(3) Average of anterior rhinorrhoea and obstruction scores. SD estimated from reported P values. Study did not report loss of sense of smell value (not statistically
significant
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Analysis 1.2. Comparison 1 High-dose versus low-dose intranasal corticosteroids, Outcome 2 Disease
severity - individual symptoms, measured as average change from baseline at 4 months (range 0 to 3).
Review: Different types of intranasal steroids for chronic rhinosinusitis
Comparison: 1 High-dose versus low-dose intranasal corticosteroids
Outcome: 2 Disease severity - individual symptoms, measured as average change from baseline at 4 months (range 0 to 3)
Study or subgroup High-dose Low-dose
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Nasal blockage
Small 2005 122 -1.1 (0.81) 115 -0.86 (0.81) 53.7 % -0.30 [ -0.55, -0.04 ]
Stjarne 2006 102 -1.09 (0.83) 102 -0.86 (0.83) 46.3 % -0.28 [ -0.55, 0.00 ]
Subtotal (95% CI) 224 217 100.0 % -0.29 [ -0.47, -0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 Rhinorrhoea
Small 2005 122 -0.74 (1.04) 115 -0.53 (0.94) 53.6 % -0.21 [ -0.47, 0.04 ]
Stjarne 2006 102 -0.74 (0.94) 102 -0.66 (0.95) 46.4 % -0.08 [ -0.36, 0.19 ]
Subtotal (95% CI) 224 217 100.0 % -0.15 [ -0.34, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
3 Loss of sense of smell
Small 2005 122 -0.54 (1.06) 115 -0.6 (0.97) 100.0 % 0.06 [ -0.20, 0.31 ]
Subtotal (95% CI) 122 115 100.0 % 0.06 [ -0.20, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 4.58, df = 2 (P = 0.10), I2 =56%
-2 -1 0 1 2
Favours high-dose Favours low-dose
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Analysis 1.3. Comparison 1 High-dose versus low-dose intranasal corticosteroids, Outcome 3 Adverse
effects: epistaxis.
Review: Different types of intranasal steroids for chronic rhinosinusitis
Comparison: 1 High-dose versus low-dose intranasal corticosteroids
Outcome: 3 Adverse effects: epistaxis
Study or subgroup Favours high-dose Low-dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chur 2013 6/51 3/50 16.7 % 1.96 [ 0.52, 7.41 ]
Penttila 2000 4/47 4/48 21.8 % 1.02 [ 0.27, 3.85 ]
Small 2005 15/122 7/115 39.6 % 2.02 [ 0.85, 4.77 ]
Stjarne 2006 13/102 4/102 22.0 % 3.25 [ 1.10, 9.63 ]
Total (95% CI) 322 315 100.0 % 2.06 [ 1.20, 3.54 ]
Total events: 38 (Favours high-dose), 18 (Low-dose)
Heterogeneity: Chi2 = 1.76, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours high-dose Favours low-dose
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Analysis 1.4. Comparison 1 High-dose versus low-dose intranasal corticosteroids, Outcome 4 Adverse
effects: local irritation.
Review: Different types of intranasal steroids for chronic rhinosinusitis
Comparison: 1 High-dose versus low-dose intranasal corticosteroids
Outcome: 4 Adverse effects: local irritation
Study or subgroup High-dose Low-dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chur 2013 (1) 1/51 2/50 39.8 % 0.49 [ 0.05, 5.24 ]
Small 2005 (2) 2/122 2/115 40.5 % 0.94 [ 0.14, 6.58 ]
Stjarne 2006 (3) 2/102 1/102 19.7 % 2.00 [ 0.18, 21.71 ]
Total (95% CI) 275 267 100.0 % 0.97 [ 0.28, 3.31 ]
Total events: 5 (High-dose), 5 (Low-dose)
Heterogeneity: Chi2 = 0.67, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours high-dose Favours low-dose
(1) Pharyngolaryngeal pain.
(2) Nasal dryness.
(3) Nasal burning.
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Analysis 1.5. Comparison 1 High-dose versus low-dose intranasal corticosteroids, Outcome 5 Nasal polyps
size, measured as change from baseline (0 to 3 range scale) at 4 months.
Review: Different types of intranasal steroids for chronic rhinosinusitis
Comparison: 1 High-dose versus low-dose intranasal corticosteroids
Outcome: 5 Nasal polyps size, measured as change from baseline (0 to 3 range scale) at 4 months
Study or subgroup High-dose Low-dose
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Small 2005 (1) 122 -0.96 (1.37) 115 -1.15 (1.37) 100.0 % 0.19 [ -0.16, 0.54 ]
Total (95% CI) 122 115 100.0 % 0.19 [ -0.16, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours high-dose Favours low-dose
(1) Measured on a scale of 0 to 3, SD imputed from P values.
Analysis 1.6. Comparison 1 High-dose versus low-dose intranasal corticosteroids, Outcome 6 Nasal polyps -
proportion with improvement at 12 weeks.
Review: Different types of intranasal steroids for chronic rhinosinusitis
Comparison: 1 High-dose versus low-dose intranasal corticosteroids
Outcome: 6 Nasal polyps - proportion with improvement at 12 weeks
Study or subgroup High-dose Low-dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Penttila 2000 (1) 18/45 11/47 100.0 % 1.71 [ 0.91, 3.21 ]
Total (95% CI) 45 47 100.0 % 1.71 [ 0.91, 3.21 ]
Total events: 18 (High-dose), 11 (Low-dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours high-dose Favours low-dose
(1) Value estimated from the percentage reported in the paper, assuming that all participants available at 12 weeks were analysed.
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL Ovid MEDLINE
#1 MeSH descriptor: [Sinusitis] explode all trees
#2 MeSH descriptor: [Rhinitis] this term only
#3 MeSH descriptor: [Rhinitis, Atrophic] this term only
#4 MeSH descriptor: [Rhinitis, Vasomotor] this term only
#5 MeSH descriptor: [Paranasal Sinus Diseases] this term only
#6 MeSH descriptor: [Paranasal Sinuses] explode all trees
#7 rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis
#8 kartagener* near syndrome*
#9 inflamm* near sinus*
#10 (maxilla* or frontal*) near sinus*
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Chronic Disease] explode all trees
#13 MeSH descriptor: [Recurrence] explode all trees
#14 chronic or persis* or recurrent*
#15 #12 or #13 or #14
#16 #11 and #15
#17 CRSsNP
#18 (sinusitis or rhinitis) near (chronic or persis* or recurrent*)
#19 #16 or #17 or #18
#20 MeSH descriptor: [Nasal Polyps] explode all trees
#21 MeSH descriptor: [Nose] explode all trees
#22 MeSH descriptor: [Nose Diseases] explode all trees
#23 #21 or #22
#24 MeSH descriptor: [Polyps] explode all trees
#25 #23 and #24
#26 (nose or nasal or rhino* or rhinitis or sinus* or sinonasal) near
(papilloma* or polyp*)
#27 rhinopolyp* or CRSwNP
#28 #19 or #20 or #25 or #26 or #27
#29 MeSH descriptor: [Steroids] explode all trees
#30 MeSH descriptor: [Adrenal Cortex Hormones] explode all
trees
#31 MeSH descriptor: [Glucocorticoids] explode all trees
#32 MeSH descriptor: [Anti-Inflammatory Agents] explode all
trees
#33 MeSH descriptor: [Anti-Inflammatory Agents, Non-
Steroidal] explode all trees
#34 #32 not #33
#35 steroid* or glucocorticoid* or corticosteroid* or glucosteroid*
or cyclocosteroid*
#36 beclomethasone or beclometasone or beclamet or beclocort
or becotide
#37 betamethasone or betadexamethasone or flubenisolone or ce-
1 exp Sinusitis/
2 paranasal sinus diseases/ or rhinitis/ or rhinitis, atrophic/ or
rhinitis, vasomotor/
3 exp Paranasal Sinuses/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).ab,ti
5 (kartagener* adj3 syndrome*).ab,ti.
6 (inflamm* adj5 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 sinus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp Recurrence/
11 (chronic or persis* or recurrent*).ab,ti.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.ab,ti.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
ab,ti
16 13 or 14 or 15
17 exp Nasal Polyps/
18 exp Nose/ or exp Nose Diseases/
19 exp Polyps/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
(papilloma* or polyp*)).ab,ti
22 (rhinopolyp* or CRSwNP).ab,ti.
23 16 or 17 or 20 or 21 or 22
24 exp Steroids/
25 exp Adrenal Cortex Hormones/
26 exp Glucocorticoids/
27 exp Anti-Inflammatory Agents/
28 exp Anti-Inflammatory Agents, Non-Steroidal/
29 27 not 28
30 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* orbeclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
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leston* or cellestoderm or betnelan or oradexon
#38 dexamethasoneor dexameth or dexone or dexametasone or
decadron or dexasone or hexadecadron or hexadrol or methylflu-
orprednisolone or millicorten
#39 flunisolide or fluticasone or hydrocortisone or cortisol or cor-
tifair or cortril or hyrocortone or cortef or epicortisol or efcortesol
or Cortisone
#40 methylprednisolone or medrol or metripred or urbason
#41 mometasone or prednisolone or precortisyl or deltacortril or
deltastab or prednesol or deltasone or prednisone or cortan or
liquid next pred or meticorten
#42 paramethasone or triamcinolone or aristocort or volon or
atolone or kenacort or orasone or panasol or prednicen
#43 corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or tri next
nasal or aristocort or Ciclesonide
#44 #29 or #30 or #31 or #34 or #35 or #36 or #37 or #38 or #
39 or #40 or #41 or #42 or #43
#45 #28 and #44
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.ab,ti
31 (corticoid* or betamethason* or betamethasone or hydrocorti-
son* or celesto* or dexamethason* or hexadecadrol or budesonid*
or horacort or pulmicort or rhinocort or methylfluorprednisolone
or flunisolid* or nasalide or fluticason* or flonase or flounce or
mometason* or nasonex or triamclinolon* or nasacort or (tri adj3
nasal) or aristocort or Ciclesonide).ab,ti
32 24 or 25 or 26 or 29 or 30 or 31
33 23 and 32
Ovid Embase Trial registries (via CRS)
1 exp sinusitis/ or paranasal sinus disease/
2 atrophic rhinitis/ or chronic rhinitis/ or rhinosinusitis/ or vaso-
motor rhinitis/
3 exp paranasal sinus/
4 (rhinosinusitis or nasosinusitis or pansinusitis or ethmoiditis or
sphenoiditis).tw
5 (kartagener* adj3 syndrome*).tw.
6 (inflamm* adj5 sinus*).tw.
7 ((maxilla* or frontal*) adj3 sinus*).tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp chronic disease/
10 exp recurrent disease/
11 (chronic or persis* or recurrent*).tw.
12 9 or 10 or 11
13 8 and 12
14 CRSsNP.tw.
15 ((sinusitis or rhinitis) adj3 (chronic or persis* or recurrent*)).
tw
16 13 or 14 or 15
17 exp nose polyp/
18 exp nose disease/ or exp nose/
19 exp polyp/
20 18 and 19
21 ((nose or nasal or rhino* or rhinitis or sinus* or sinonasal) adj3
ClinicalTrials.gov
Condition: rhinitis OR sinusitis OR rhinosinusitis OR (nose
AND polyp*) OR (nasal AND polyp*) OR CRSsNP OR CR-
SwNP OR CRS
ICTRP
Title: rhinitis OR sinusitis OR rhinosinusitis OR CRSsNP OR
CRSwNP OR CR
OR
All: (nose AND polyp*) OR (nasal AND polyp*)
NB These searches were run from 1 March 2015 to 11 August 2015,
when these terms were last searched to populate the Cochrane ENT
trials register in CRS
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(papilloma* or polyp*)).tw
22 (rhinopolyp* or CRSwNP).tw.
23 16 17 or or 20 or 21 or 22
24 exp *corticosteroid/
25 exp steroid/
26 exp antiinflammatory agent/
27 exp nonsteroid antiinflammatory agent/
28 26 not 27
29 (steroid* or glucocorticoid* or corticosteroid* or glucos-
teroid* or cyclocosteroid* or beclomethasone or beclometasone or
beclamet or beclocort or becotide or betamethasone or betadexam-
ethasone or flubenisolone or celeston* or cellestoderm or betnelan
or oradexon or dexamethasone or dexameth or dexone or dexam-
etasone or decadron or dexasone or hexadecadron or hexadrol or
methylfluorprednisolone or millicorten or flunisolide or fluticas-
one or hydrocortisone or cortisol or cortifair or cortril or hyrocor-
tone or cortef or epicortisol or efcortesol or Cortisone or methyl-
prednisolone or medrol or metripred or urbason or mometasone
or prednisolone or precortisyl or deltacortril or deltastab or pred-
nesol or deltasone or prednisone or cortan or liquid next pred
or meticorten or paramethasone or triamcinolone or aristocort or
volon or atolone or kenacort or orasone or panasol or prednicen)
.tw
30 24 or 28 or 29
31 23 and 30
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
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(Continued)
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
1This should be the people who received the treatment and were therefore not considered ’drop-outs’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Polyps status: x % with polyps/no information [add info on
mean polyps score if available]
• Previous sinus surgery status: [x% with previous surgery]
• Previous courses of steroids: [add info on mean number of
courses if available]
Other important effect modifiers, if applicable (e.g. aspirin sensi-
tivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
75Different types of intranasal steroids for chronic rhinosinusitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects: [review specific]
Secondary outcomes:
• Health-related quality of life, generic
• [Other review specific, pre-specified adverse events]
• [Other review specific, pre-specified adverse events]
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: “…”
Comment:
Allocation concealment (selection bias) Quote: “…”
Comment:
Blinding of participants and personnel
(performance bias)
Quote: “…”
Comment:
Blinding of outcome assessment (detection
bias)
Quote: “…”
Comment:
Incomplete outcome data (attrition bias) Quote: “…”
Comment:
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(Continued)
Selective reporting (reporting bias) Quote: “…”
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: “…”
Comment:
Other bias (see section 8.15) Quote: “…”
Comment:
Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
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(Continued)
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
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No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Epistaxis/nose
bleed
INCS
Saline irrigation
Local irritation
(sore throat, oral
thrush, discom-
fort)
INCS
Saline irrigation
Os-
teoporosis (min-
imum 6months)
INCS
Stunted growth
(children, mini-
mum 6 months)
INCS Can also be mea-
sured as average
height
Mood
disturbances
OCS
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
iting, stomach ir-
ritation)
OCS
Antibiotics
Insomnia OCS
Os-
teoporosis (min-
imum 6months)
INCS
OCS
Discomfort Saline irrigation
Skin irritation Antibiotics
Anaphylaxis
or other serious
allergic reactions
such as Stevens-
Johnson
Antibiotics
Comments:
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Appendix 3. Forest plots
Please see Figure 4; Figure 5.
Figure 4. Forest plot of comparison: 1 High-dose versus low-dose intranasal corticosteroids, outcome: 1.1
Disease severity - overall symptoms, measured as average change from baseline at 4 months (range 0 to 3).
Figure 5. Forest plot of comparison: 1 High-dose versus low-dose intranasal corticosteroids, outcome: 1.2
Disease severity - individual symptoms, measured as average change from baseline at 4 months (range 0 to 3).
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C O N T R I B U T I O N S O F A U T H O R S
Lee Yee Chong: scoped, designed and wrote the protocol (Chong 2015), screened abstracts, extracted data, conducted the analysis and
wrote up the review.
Karen Head: reviewed and edited the protocol, screened abstracts, extracted data, helped to check the analysis and contributed to the
writing of the review.
Claire Hopkins: clinical guidance at all stages of project scoping, protocol development and data interpretation. Commented on drafts
of the review.
Carl Philpott: clinical guidance at all stages of project scoping, protocol development and data interpretation. Contributed to the
writing of the review.
Martin J Burton: helped todraft the protocol; clinical guidance at all stages of project scoping andprotocol development, and contributed
to the writing of the review.
Anne GM Schilder: commented on drafts and contributed to the writing of the review.
D E C L A R A T I O N S O F I N T E R E S T
Lee Yee Chong: none known.
Karen Head: none known.
Claire Hopkins: I have received financial support from several companies involved in producing instruments for sinus surgery: Acclarent,
Sinusys, Cryolife and Medtronic.
Carl Philpott: I have previously received consultancy fees from the companies Acclarent, Navigant, Aerin Medical and Entellus.
Martin J Burton: Professor Martin Burton is joint Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process for
this review.
Anne GM Schilder: Professor Anne Schilder is joint Co-ordinating Editor of Cochrane ENT, but had no role in the editorial process
for this review. Her evidENT team at UCL is supported by her NIHR Research Professorship award with the remit to develop a UK
infrastructure and programme of clinical research in ENT, Hearing and Balance. Her institution has received a grant from GSK for a
study on the microbiology of acute tympanostomy tube otorrhoea.
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• No sources of support supplied
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External sources
• National Institute for Health Research, UK.
Funding to complete a suite of reviews on medical interventions for chronic rhinosinusitis in 2015/2016 (award reference 14/174/
03), in addition to infrastructure funding for Cochrane ENT
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As part of the discussions about the use of a total symptoms score we noted that many papers within the suite of reviews did not present
information for all four elements of the EPOS criteria for defining chronic rhinosinusitis (EPOS 2012). In particular, many studies
that only included patients with nasal polyps did not present information on facial pressure or pain. We made the decision that where
individual symptoms were recorded, they should be presented within the outcome of disease severity symptom score within the paper
as this information would be useful for the reader.
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